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AMIDATED DOPAMINE NEURON 
STIMULATING PEPTIDE RESTORATION OF 
MITOCHONDRIAL ACTIVITY 
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a 371 application of PCT/US2007/022696 filed Oct. 26, 
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priority under 35 U.S.C. §119(e) to U.S. Provisional Appli-
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STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with U.S. govermnent support 
under grant numbers POl AG13494, P50 NS39787-01, R03 
NS07 5 694 and T32 AG00024 2 awarded by theN ational Insti-
tutes of Health. The U.S. govermnent has certain rights in the 
invention. 
FIELD OF THE INVENTION 
The present invention relates to novel proteins, referred to 
herein as ami dated glial cell line-derived neurotrophic factor 
(GDNF) peptides (or "Dopamine Neuron Stimulating pep-
tides" ("DNSP") or "Amidated Dopamine Neuron Stimulat-
ing peptides" ("ADNS peptides")), that are useful for treating 
brain diseases, injuries that result in dopaminergic deficien-
cies, and diseases or conditions associated with inhibition of 
mitochondrial activity. 
BACKGROUND OF THE INVENTION 
Neurotrophic factors are endogenous proteins that modu-
late cell signaling pathways regulating stem cell proliferation, 
neuronal differentiation, differentiation, growth and regen-
eration (Barde Y., Neuron 2:1525-1534 (1989); Gotz, R., et 
a!., Camp Biachem Physial Pharmacal Taxical Endacrinal 
108: 1-10 (1994); and Goldman, S. A., J. Neurabial36: 267-
86 (1998)). They are generally small, soluble proteins with 
molecular weights between 13 and 24 KDa and often function 
as homodimers. Because of this physiological role, neu-
rotrophic factors are useful in treating the degeneration of 
nerve cells and the loss of differentiated function that occurs 
in a variety ofneurodegenerative diseases. 
Many neurotrophic factors are both neuroprotective (pro-
tecting neurons from injury) and neurorestorative (promoting 
structural and functional regeneration). The best defined pro-
tective functions are seen during neural development. During 
development, excessive numbers of neurons are generated in 
many brain regions. 
Developing neurons that fail to make connections with 
appropriate trophic factor producing target cells are deprived 
of necessary neurotrophic factors and die. Those neurons that 
establish connections survive and function properly (e.g. 
NGF; see Campenot, R. B. and Macinnis, B. L, J Neurabial 
58:217-229 (2004)). Neurotrophic factors are also capable of 
promoting the re-growth of damaged neurons and their pro-
2 
cesses both in vitro and in animal models (see Lad, S. P. eta!., 
J Bial Chern 278: 24808-24817 (2003a) and Lad, S.P. eta!., 
Curr Drug Targets CNS Neural Disard 2: 315-334 (2003b )). 
Identifying neurotrophic factors with the right combination 
5 of protective and restorative actions and developing effective 
strategies for drug delivery have profound therapeutic impli-
cations for Parkinson's disease, Alzheimer's disease, Hun-
tington's disease and other degenerative processes in the 
brain (including those induced by brain injury). 
10 Glial cell line-derived neurotrophic factor (GDNF) is a 
trophic factor shown to dramatically protect and enhance the 
function of dopamine neurons in vitro and in vivo in rodents 
and monkeys (Beck, K. D., eta!, Nature, 373:339-41 (1995); 
15 
and Bjorklund, A., et a!., "Brain Res., 886:82-98 (2000), 
Gash, D. M., eta!., Nature, 380:252-255 (1996); Grondin, R., 
eta!., Brain, 125:2191-2201 (2002); Grondin, R., eta!., J. 
Neurasci., 23:1974-1980 (2003); Hebert M. A., et a!., J. 
Pharm. Exp. Ther., 279:1181-1190 (1996); Hebert M.A. and 
20 Gerhardt, G. A., "J. Pharm. Exp. Ther., 282:760-768 (1997); 
Hou, J. G. G., eta!., J. Neurachem., 66:74-82 (1996); Kor-
dower, J. H., eta!., Ann Neural., 46(3):419-424 (1999); Kor-
dower, J. H., eta!., Science, 290:767-773 (2000); Palfi, S., et 
a!., J. Neurasci., 22:4942-4954 (2002); Tomac, A., et a!., 
25 Nature, 373:335-339 (1995)). 
The current standard treatment, levodopa, is palliative and 
does not prevent the relentless progression of Parkinson's 
degeneration. GDNF exerts effects on dopamine neurons that 
slow the process of Parkinson's disease and even reverses 
30 some of the degenerative changes. Preclinical studies con-
ducted to date suggest that GDNF exerts at least three general 
trophic actions on dopamine neurons in the substantia nigra: 
pharmacological upregulation, restoration and neuroprotec-
tion. With regard to pharmacological upregulation, GDNF 
35 upregulates dopaminergic functions, such as increasing the 
evoked release of dopamine (Gerhardt, G. A. eta!., Brain Res 
817: 163-171 (1999) andGrondinet a!., 2003). It also appears 
to modulate the phosphorylation ofTH (Salvatore, M. eta!. J 
Neurachem. 90:245-54., (2004)). With regard to restoration, 
40 GDNF increases the number of neurons expressing the 
dopamine markers TH and DAT in the substantia nigra (Gash 
eta!., 1996; Kordower eta!., 2000; and Grondin eta!., 2002). 
This suggests that one trophic action is to stimulate recovery 
of injured/quiescent nigra! neurons. Supporting this interpre-
45 tation is the consistent observation that GDNF promotes 
increases in dopamine neuron perikarya) size and the number 
of neurites. With regard to neuroprotection, nigrostriatal 
administration of GDNF either shortly before or following a 
neurotoxic challenge (e. g. 6-0 HDA, methy !-amphetamine or 
50 MPTP) protects dopamine neurons from injury in rodents and 
nonhuman primates (Kordower eta!., 2000 and Fox, C.M., 
Brain Res 896:56-63 (2001)). 
Accordingly, GDNF therapy is expected to be helpful in 
the treatment of nerve damage caused by conditions that 
55 compromise the survival and/or proper function of one or 
more types of nerve cells. Such nerve damage may occur from 
a wide variety of different causes. Nerve damage may occur 
to one or more types of nerve cells by, for example: (1) 
physical injury, which causes the degeneration of the axonal 
60 processes and/or nerve cell bodies near the site of injury; (2) 
temporary or permanent cessation ofblood flow to parts of the 
nervous system, as in stroke; (3) intentional or accidental 
exposure to neurotoxins, such as chemotherapeutic agents 
(e.g., cisplatinum) for the treatment of cancer, dideoxycyti-
65 dine (ddC) for the treatment of AIDS; (4) chronic metabolic 
diseases, such as diabetes or renal dysfunction; or (5) neuro-
degenerative diseases such as Parkinson's disease, Alzhe-
US 9,402,875 B2 
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imer's disease, and Amyotrophic Lateral Sclerosis (ALS), 
which result from the degeneration of specific neuronal popu-
lations. 
GDNF therapy may be particularly helpful in the treatment 
of neurodegenerative conditions involving the degeneration 
of the dopaminergic neurons of the substantia nigra, such as 
Parkinson's disease. The expected impact ofGDNF therapy 
is not just to produce an increase in the dopaminergic neu-
rotransmission at the dopaminergic nerve terminals in the 
striatum (which will result in a relief of the symptoms), but 
also to slow down, or even stop, the progression of the degen-
erative processes and to repair the damaged nigrostriatal path-
way and restore its function. GDNF may also be used in 
treating other forms of damage to or improper function of 
dopaminergic nerve cells in human subjects. Such damage or 
malfunction may occur in schizophrenia and other forms of 
psychosis. The only current treatments for such conditions 
are symptomatic and require drugs which act upon dopamine 
receptors or dopamine uptake sites, consistent with the view 
that the improper functioning of the dopaminergic neurons 
which innervate these receptor-bearing neuronal populations 
may be involved in the disease process. 
However, initial clinical trials involving ventricular deliv-
ery of GDNF showed no statistically significant differentia-
tion of the placebo and active treatment groups (Nutt, J. G. et 
a!., Neurology 60: 69-73 (2003)), perhaps because insuffi-
cient amounts of GDNF reached critical target sites from the 
CSF (Ai, Y. eta!., J Camp Neurol461: 250-26125 (2003); and 
Kordower, J. H., et a!. (2000)). In addition, a phase 2 trial 
evaluating intraputamenal delivery of glial cell line-derived 
neurotrophic factor (GDNF) for the treatment of Parkinson's 
disease failed to achieve its primary end point, a 25% 
improvement on the Unified Parkinson Disease Rating Scale 
(UPDRS) motor score "off' medication after six months of 
treatment (Lang, A. E. eta!., Ann Neurol59:459-466 (2006)). 
There are strong indications from studies in rhesus monkeys 
using the same delivery system and protocol followed in the 
phase 2 study that drug bioavailability significantly contrib-
uted to the failure of the trial (Salvatore et a!., Exp Neural 
202(2):497-505 (2006)). The concentration ofGDNF around 
the catheter tip and limited diffusion into surrounding brain 
parenchyma was limited to a brain volume representing 2-9% 
of the human putamen. Thus GDNF distribution in the phase 
4 
in some monkeys receiving high levels of GDNF in a toxi-
cology study (see Sherer, T. B., eta!., Movement Dis 21:136-
141 (2006)). Another possible side-effect is aberrant sprout-
ing and tyrosine hydroxylase downregulation of the 
nigrostriatal dopaminergic pathway in rats exposed to high 
GDNF levels from viral vector gene transfer (Georgievska, 
B., et a!, Neuroreport 13: 75-82 (2002)). Also, increased 
neuronal death has been reported in rats with elevated GDNF 
from viral vector gene transfer in a stroke model (Arvidsson, 
10 A. eta!., Neurobiol Dis 14: 542-556, (2003)). 
While GDNF has not met the criteria for clinical efficacy in 
the two phase 2 trials conducted to date (Nutt et a!., 2003; 
Lang eta!., 2006), it appears to be the most potent dopamin-
ergic trophic factor found to date. Thus, the ideal drug for 
15 treating Parkinson's disease and other neurodegenerative 
processes in the brain would possess the positive trophic 
actions ofGDNF. Delivery could be targeted to the appropri-
ate brain area by any of a number of methods including direct 
infusion, viral vectors or even nasal sprays. In particular, 
20 biologically active peptides with trophic actions may offer 
many of the desired properties. To date, such biologically 
active peptides have not been identified. 
A crude peptide extract from the brain cerebrolysin has 
been tested in human studies, with modest effects reported 
25 (Lukhanina, E. P. eta!., Zh Nevrol Psikhiatr Im S S Korsakova 
104: 54-60 (2004)). Three small molecule compounds have 
also been tested in Parkinson's disease patients: the tripeptide 
glutathione, tocopherol, and Coenzyme Q 10 (Weber, C. A., et 
a!., Ann Pharmacother 40: 935-938 (2006)). The three small 
30 molecule compounds also appear to have only minor benefits 
for patients. 
Consequently, there continues to exist a long-felt need for 
effective agents and methods for the treatment and prevention 
of brain diseases and injuries that result in dopaminergic 
35 deficiencies. Accordingly, it is an object of the present inven-
tion to provide agents for treating and preventing such dis-
eases and injuries in a subject, comprising novel amidated 
GDNF -derived peptides that have dopaminergic trophic fac-
tor activity. This and other such objectives will be readily 
40 apparent to the skilled artisan from this disclosure. 
SUMMARY OF THE INVENTION 
2 trial was likely limited to a small brain region, and could 
affect only a limited segment of the brain undergoing parkin- 45 
sonian degeneration. 
The present invention provides a method for treating a 
brain disease or injury resulting in dopaminergic deficiencies, 
or diseases and conditions associated with mitochondrial dys-
function, e.g., diseases and conditions associated with inhib-
ited or reduced levels of complex I enzyme (NADH: 
ubiquinone oxidoreductase) activity. Treating a brain disease 
includes, e.g., relieving the symptoms of the disease or con-
dition, as well as slowing down, or even stopping, the pro-
gression of the disease, including the repair or the damaged 
nigrostriatal pathway and restoring its function. The methods 
comprise administering a pharmaceutically effective amount 
Successful trophic factor therapy requires site-specific 
delivery and distribution of the trophic factor throughout the 
target tissue (the putamen for Parkinson's disease). The blood 
brain barrier effectively blocks entry from blood borne pro- 50 
teins, including trophic factors. Infusions into the cerebrospi-
nal fluid are not effective in humans because ofbrain size and 
may produce unwanted side effects by stimulating other 
trophic factor responsive populations such as sensory neu-
rons. 55 of a composition comprising at least one of the following 
peptides: (a) a purifiedADNS peptide comprising the amino 
acid sequence ERNRQAAAANPENSRGK-amide (SEQ ID 
NO: 2); (b) a purified ADNS peptide comprising the amino 
acid sequence FPLPA-amide (SEQ ID NO: 3); and (c) a 
In addition to focal delivery into the appropriate site, the 
delivery must be tightly regulated. Regardless of the method 
used to deliver GDNF (i.e., direct infusion, stem cells, encap-
sulated cells, gene therapy) prolonged elevated levels of 
GDNF in the brain outside of the target area may produce 
adverse side-effects. Circulating antibodies to GDNF are one 
possible outcome and it is quite typical to find antibodies to 
endogenous proteins used therapeutically (e.g. beta inter-
feron and insulin, see Durelli, L., eta!., Front Biosci 9: 2192-
2204 (2004) and Stoever, J. A. eta!., Diabetes Techno! Ther 4: 
157-161 (2002) ). The effects of circulating GDNF antibodies 
are not known. Focal Purkinje cell lesions have been reported 
60 purified ADNS peptide comprising the amino acid sequence 
PPEAPAEDRSL-amide (SEQ ID NO: 4), to a subject in need 
thereof wherein the composition also comprises at least one 
of a pharmaceutically acceptable vehicle, excipient, and dilu-
ent. Preferably, the subject is a mmal, and most preferably, 
65 the subject is human. The methods also encompass amelio-
rating or inhibiting the effects of a mitochodrial toxin, e.g., a 
mitochodrial complex I toxin, by contacting mitochodria or 
US 9,402,875 B2 
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behavior (A) and significantly increased levels of dopamine 
and the dopamine metabolite, DO PAC, by about 100% in the 
substantia nigra (B). 
FIG. 20A-I demonstrate the protective effect ofDNSP-11 
on MN9D and B65 cells incubated with rotenone, MPP+ or 
TaC!o as determined in JC-1 mitochodrial membrane poten-
tial assay (A-D), a TUNEL assay (E-G)and Capase 3 assay 
(H-I). 
cells comprising mitochondria with at least one of (a) a puri-
fied ADNS peptide comprising the amino acid sequence 
ERNRQAAAANPEN-SRGK-amide (SEQ ID NO: 2); (b) a 
purified ADNS peptide comprising the amino acid sequence 
FPLPA-amide (SEQ ID NO: 3); and (c) a purified ADNS 5 
peptide compnsmg the amino acid sequence 
PPEAPAEDRSL-amide (SEQ ID NO: 4) or truncated frag-
ments thereof in an amount and for a time sufficient to ame-
liorate or inhibit the effects of the mitochondrial toxin. FIG. 21 depicts the effect of GDNF and DNSP-11 on 
10 Erk1/2 activation. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 depicts the nucleotide sequence (top strand) and 
amino acid sequence (bottom strand) of mature human 
GDNF (SEQ ID NO: 5 and SEQ ID NO: 1). 
FIG. 2 depicts the post-translational processing of splice 
form 1 of human GDNF. Sequences from top to bottom are: 
SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 
FIG. 22 depicts the evaluation of DNSP-11's effect on 
oxygen consumption rates in MN9D cells. 
FIG. 23 depicts the oxygen consumption rate of MN9D 
cells exposed to TaC!o (A) or rotenone (B) with or without 
15 DNSP-11. 
DETAILED DESCRIPTION OF THE INVENTION 
9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID 
NO: 13, SEQ ID NO: 3, SEQ ID N0:4, and SEQ ID NO: 2. 20 
Human glial cell line-derived neurotrophic factor 
(hGDNF) is synthesized as a precursor that is processed and 
secreted as a mature protein of 134 amino acids. Mature 
human GDNF has the amino acid sequence depicted in FIG. 
1 (SEQ ID NO: 1 ). 
FIG. 3 depicts the precursor segments of the ADNS pep-
tides ERNRQAAAANPENSRGK-amide(SEQ ID NO: 2), 
FPLPA-amide (SEQ ID N0:3), and PPEAPAEDRSL-amide 
(SEQ ID N0:4). From top to bottom SEQ ID NO: 8, SEQ ID 
NO: 14, and SEQ ID N0:15. 
FIG. 4 depicts the average K+ -evoked release of dopamine 
in Fischer 344 rats treated withADNS peptides. 
FIG. 5 depicts the increase in major metabolites of dopam-
ine in Fischer 344 rats treated withADNS peptides. 
The present invention is related to the realization that 
25 human GDNF (splice form 1) precursor protein conforms to 
a rather exacting sequence profile characteristic of neuropep-
tide precursor proteins. GDNF is expressed in at least three 
isoforms that result from alternative splicing of mRNA. Pro-
FIG. 6 depicts the increased survival of dopamine neurons 30 
in cell cultures treated withADNS peptides. 
teins expressed from these RNA splice variants differ in their 
N-terminal regions (see NCBI entry NP 000505 for isoform 
1; NCBI entry NP 964701 for isoform 2; and NCBI entry NP 
954704 fori so form 3). Isoforms 1 and 2 are secretory protein 
precursors with N-terminal signal peptides. Isoform 3 is 
likely a nuclear-targeted protein with a nuclear localization 
FIGS. 7 A and B depict the results of in vivo microdialysis 
used to investigate the dynamics of dopamine release in the 
basal ganglia of the right putamen following treatment with 
ADNS peptides. 
FIGS. SA-F depict the histopathological response to the 
injection of ADNS peptides in the nigra! region using stan-
dard histochemical techniques. 
35 signal (NLS), but no sianal peptide. The three isoforms are 
differentially expressed, apparently under regulatory control. 
FIGS. 9A-D depict a series of photomicrographs evaluat-
ing the substantia nigra compacta (SNc) containing the popu- 40 
lation of dopamine neurons that degenerates in Parkinson's 
disease after treatment with ADNS peptides. 
FIGS. 1 OA and B depict the sequence origin and homology 
of dopamine neuron stimulating peptide-11 (DNSP-11 ). 
FIGS. llA-D depict the neurotropic effects of DNSP-11 45 
andGDNF on mesencephalic (A and B) andMN9D (C and D) 
dopaminergic cells. 
FIGS. 12A-C depict the effects ofDNSP-11 in normal (A) 
and unilateral 6-0HDA-lesioned (B and C) rats. 
FIG. 13 depicts the interactions of DNSP-11 with protein 50 
partners. 
FIG. 14 depicts the gel filtration analysis of the interaction 
between GAPDH and GDNF. 
All of the isoforms contain the sequence that is considered 
mature GDNF with "full biological activity" (residues 
78-211 in isoform 1). In fact, recombinant proteins further 
truncated at theN-terminus are purported to have the "full 
biological activity". From the fact that three separate precur-
sors of the same GDNF molecule are expressed under sepa-
rate regulation, two with signal peptides and the third with a 
probable nuclear localization signal, suggests that there are 
both nuclear and cell surface receptors for GDNF. 
The separately regulated expression of two different secre-
tory isoforms (isoforms 1 and 2) suggests a biologically sig-
nificant function for the different N-terminal sequences of the 
isoforms. The conventional wisdom is that residues 20-77 of 
isoform 1 precursor constitute a "domain propeptide". The 
present invention provides a new interpretation of the impor-
tance of the 20-77 "domain propeptide" region of isoform 1 
precursor. The "domain propeptide" segment of isoform 1 
precursor is the metabolic precursor of two small amidated FIGS. 15A-C depict the solubility and stability ofDNSP-
11 at various storage and experimental conditions. 
FIG.16 shows the effects of citrate vehicle or DNSP-11 on 
resting levels of DO PAC one month after a single infusion. 
FIG. 17 shows the broad distribution ofDNSP-11 in the rat 
substantia nigra region of the midbrain within 30 minutes of 
DNSP-11 injection (panels A-F). 
55 peptides, according to well established enzymatic pathways 
for release of peptide amide hormones and neuropeptides 
from their precursor proteins. The two small amidated pep-
tides are FPLPA-amide (SEQ ID NO: 3)and 
FIG. 18 shows the DNSP-11 increased State III oxygen 
consumption vs. vehicle in both the SN and striatum, 28 days 
post bilateral intranigral injections (*p<0.05 vs control, two-
tailed, unpaired tests). (A) Substantia nigra 28 days; (B) Stria-
tum 28 days. 
FIG. 19 demonstrates that DNSP-11 produced a signifi-
cant, about 50%, decrease in apomorphine-induced rotational 
60 
PPEAPAEDRSL-amide (SEQ ID NO: 4). 
Furthermore, a third small amidated peptide, ERN-
RQAAAANPENSRGK-amide (SEQ ID NO: 2), may be 
released from consensus enzymatic processing of residues 
88-110 of the isofonn 1 precursor. This consensus peptide 
amide precursor occupies the N-terminal sequence of 
65 "mature GDNF", which is presumably not critical or at least 
includes residues that are not critical for biological activity, 
according to the patent literature. The isoform 2 precursor 
US 9,402,875 B2 
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contains the sequence FPLPA (SEQ ID NO: 6), but does not 
contain the amidation signal (GKR, residues 25-27) in the 
case of I so form 1 precursor. Isoform 2 is not, in other words, 
8 
Furthermore this invention relates to method for treating or 
preventing the effects induced by toxins, e.g., pesticides and 
solvents, particularly mitochondrial Complex I toxins, e.g., 
rotenone, MPP+, MPTP, and TaClo, by contacting mitochon-
dria or mitochondria-containing cells in need thereof with the 
ADNS peptides of this invention in an amount and for suffi-
cient duration to treat or prevent the effects of the mitochon-
drial toxins. The mitochondria and cells may be contacted 
with the ADNS peptides of this invention prior to, during, 
a potential precursor of FPLPA-amide (SEQ ID NO: 3) 
according to known enzymatic pathways. I so form 3 does not 
contain the sequence FPLPA at all, so likewise can not be a 
metabolic precursor ofFPLPA-amide (SEQ ID NO: 3). Both 
isoforms 1 and 2 are consensus precursors of ERN-
RQAAAANPENSRGK-amide (SEQ ID NO: 2), but isoform 
3 is not. 10 and/or after exposure to the toxin. 
Thus, human GDNF isoform 1 is a secretory protein that 
can potentially yield three small amidated peptides by con-
sensus enzymatic pathways known to release peptide amide 
hormones andneuropeptides from their known precursor pro-
teins. This is a rare combination of enzymatic processing 15 
motifs and strongly suggests that GDNF isoform 1 precursor 
is the metabolic precursor of up to three small ADNS pep-
tides, in addition to the larger C-terminal domain that is 
widely supposed to posses the "full biological activity" of 
GDNF. C-terminal amidation in natural peptides is highly 20 
correlated with receptor mediated signal transduction: about 
half of the known peptide hormones and neuropeptides and 
C-terminal amidation is rare and almost unknown among 
other pep tides of biological origin. 
Animal studies with synthetic peptides corresponding to 25 
the consensus products of Isoform 1 precursor protein are 
consistent with some or all of these pep tides being biologi-
cally active and involved in regulation of dopamine metabo-
lism. This is to be expected from a protein that yields multiple 
biologically active regulatory peptides in a fixed molar ratio. 30 
The fact that the different Isoforms of GDNF precursor pro-
tein are consensus precursors of different combinations of 
amidated peptides in addition to GDNF, suggests a reason for 
differential expression of three separate isoforms (in addition 
Thus an embodiment of this invention is a method for 
protecting or restoring mitochondrial activity, by contacting 
mitochodria, mitochondria-containing cells, or a subject, 
having reduced mitochondrial activity with a purified ADNS 
peptide of this invention, e.g., a purified comprising the 
amino acid sequence ERNRQAAAANPENSRGK-amide 
(SEQ ID NO: 2), FPLPA-amide (SEQ ID NO: 3); or 
PPEAPAEDRSL-amide (SEQ ID NO: 4), or mixtures 
thereof, or fragments thereof (for example nested fragments), 
in an amount and for suffient time to restore, at least partially, 
mitochondrial activity, particularly complex I enzyme activ-
ity. The reduced mitochondrial activity may be the result of 
the effects of the toxin, e. g., a toxin that inhibits mitochondria 
complex I enzyme (NADH:ubiquinone oxidoreductase) 
activity, a traumatic brain injury, a spinal cord injury, or a 
genetic condition that results in mitochodrial dysfunction, 
particularly a reduction in complex I enzyme activity. In an 
embodiment of the invention the mitochondria, mitochon-
dria-containing cells or subject having mitochondrial dys-
function, particularly reduced complex I enzyme activity, 
may be treated by contacting the mitochondria, cells or sub-
ject with the ADNS peptide of this invention, in an amount 
and for a time sufficient to restore, at least partially, mitochon-
drial activity, preferably complex I enzyme activity. For 
to differential secretory and nuclear routing). 35 examples, where mitochondrial activity has been reduced in 
response to a traumatic brain injury or a spinal cord injury or 
a genetic condition, the peptides may be administered to the 
subject within minutes, hours, days or weeks of the injury, in 
According to this model, splice form 1 of human GDNF 
may be post-translationally processed in vivo to yield three 
small amidated peptides, as indicated in FIG. 2. These small 
amidated peptides may mediate some or all of the biological 
effects of GDNF. The present invention is based on the unex- 40 
pected discovery that these small amidated fragments of the 
mature GDNF protein retain the biological activity ofGDNF. 
Thus, theADNS peptides of the present invention include 
these three small ami dated peptides, which are represented by 
the amino acid sequences ERNRQAAAANPENSRGK- 45 
amide; FPLPA-amide; and PPEAPAEDRSL-amide (SEQ ID 
NOs:2, 3, and 4, respectively). 
The ADNS pep tides of the present invention are useful for 
treatment and prevention of neurodegenerative conditions 
involving dopaminergic deficiencies, such as Parkinson's dis- 50 
ease, age-associated motor and cognitive slowing, and other 
diseases and injuries to the brain, e.g., Alzheimer's Disease. 
Also an embodiment of this invention is a method for treating 
neurodegenerative conditions associated with mitochondrial 
dysfunction, particularly reduced mitochondrial Complex I 55 
enzyme activity, by administering the peptides of this inven-
tion to a subject in need thereof in an amount and for a time 
sufficient to treat or prevent the condition. Such conditions 
include, e.g., early onset Parkinson's Disease, Bipolar disor-
der, Schizophrenia, ALS, traumatic brain injury, spinal cord 60 
injury, stroke, congenital diseases, Leber's hereditary optic 
neuropathy, Leigh Syndrome, encephalomyopathy, mito-
chondrial myopathy, encephalopathy, lactic acidosis, and 
stroke-like episodes (MELAS), myoclonic epilespy and 
ragged-red fiber disease (MERFF), particularly early onset 65 
Parkinson's Disease, traumatic brain injury, spinal cord 
injury, orALS. 
a therapeutically effective amount and for a time sufficient to 
restore at least partial mitochondrial function and alleviate 
symptoms associated with mitochondrial dysfunction. The 
peptides may be administered in a single dose or in multiple 
doses over a prolonged period of time suffient to reduce the 
symptoms associated with a reduction in mitochondrial activ-
ity, particularly complex I enzyme activity. The subject is 
preferably a mammal, e.g., a human. 
Another embodiment of the invention is a method for treat-
ing a subject prior to exposure to a mitochondrial toxin com-
prising administering to a subject a pharmaceutically effec-
tive amount of a composition comprising a purified ADNS 
peptide before exposure to a mitochondrial toxin. For 
example the ADNS peptide may be peptide comprising the 
amino acid sequence ERNRQAAAANPENSRGK-amide 
(SEQ ID NO: 2) or FPLPA-amide (SEQ ID NO: 3); or 
PPEAPAEDRSL-amide (SEQ ID NO: 4), or mixtures 
thereof, or nested fragments thereof, and at least one of a 
pharmaceutically acceptable vehicle, excipient, and diluent. 
TheADNS peptide may be administered to the subject in an 
amount and for a time sufficient to treat the effects of the 
mitochondrial toxin. For example, theADNS peptide(s) may 
be administered to the subject within 24 hours, within 12 
hours, within 3 hours, within 1 hour, within 30 minutes, or 
within 1 minute before being exposed to the toxin or is admin-
istered to the subject concommitantly with exposure to the 
toxin. In another embodiment, the ADNS peptides of this 
invention are administered to a subject after the subject is 
exposed to the toxin, preferably within minutes, hours, days, 
US 9,402,875 B2 
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SEQ ID NOs:2, 3, or 4 that is preferably at least 70%, most 
preferably at least 80%, and even more preferably at least 
90% or even 95%. 
weeks or months of being exposed to the toxin, in a therapeu-
tically effective amount for a time sufficient to restore at least 
partial mitochondrial function and alleviate symptoms asso-
ciated with mitochondrial dysfunction, particularly a reduc-
tion in complex I enzyme activity. The subject is preferably a 
mammal, e.g., a human. Alternatively, the mitochodria, cells 
containing mitochondria or the subject may be treated con-
currently with exposure to the toxin, for at least for part of the 
time that the mitochondria or cells are exposed to the toxin. In 
another alternative of the invention, the peptides may be 
contacted with the mitochondria, mitochondria-containing 
cells after the mitochondria or cells have been exposed to the 
toxin. 
As used herein, the term "ADNS peptide," "peptide 
amide," or "amidated peptide" means a peptide comprising 
the group -CONH2 at the C-terminal end. This amidation 
occurs in vivo, once the peptides are formed by the enzyme, 
peptidylglycine amidating monooxygenase (PAM). The 
ADNS peptides of the present invention can be readily 
10 obtained in a variety of ways, including, without limitation, 
recombinant expression, purification from natural sources, 
and/or chemical synthesis. Preferably, the ADNS peptides 
can be chemically synthesized by commercial venders. The 
15 
ADNS peptides used in the present examples were synthe-
sized using tBOC chemistry and at a single scale range (which 
generates a theoretical crude yield of 500-1,000 mg for a 
10-20 mer respectively), by the Keck Biotechnology 
The small ADNS peptides of this invention are easily 
within the range of synthetic production methods, so that the 
molecules could be subjected to rigorous structure-activity 
studies to optimize pharmacological activities and biostabil-
ity. In addition, as the difficulties in delivering GDNF clini-
cally may well be related to the fact that recombinant GDNF 20 
is not properly processed into active forms, the small ADNS 
peptides may overcome some of these difficulties. Finally, 
small peptides are generally much less antigenic than proteins 
and can be synthesized free of the trace host protein contami-
nants always present in recombinant proteins. 
Resource Laboratory at Yale University (New Haven, Conn.). 
ADNS peptide pharmaceutical compositions typically 
include a therapeutically effective amount of at least one of a 
ADNS peptide represented by SEQ ID NOs:2, 3, and 4 in 
admixture with one or more pharmaceutically and physi-
ologically acceptable formulation materials. Suitable formu-
25 lation materials include, but are not limited to, antioxidants, 
preservatives, coloring, flavoring and diluting agents, emul-
sifYing agents, suspending agents, solvents, fillers, bulking 
agents, buffers, delivery vehicles, diluents, excipients and/or 
pharmaceutical adjuvants. For example, a suitable vehicle 
The small ADNS pep tides of the present invention include 
biologically active synthetic or recombinant ADNS peptides, 
ADNS peptides produced from GDNF, biologically active 
ADNS peptide variants (including insertion, substitution, and 
deletion variants), and chemically modified derivatives 
thereof. Also included are biologically active ADNS peptide 
variants that are substantially homologous to any one of the 
ADNS peptides having the amino acid sequence set forth in 
SEQ ID NOs:2, 3, or 4. The peptides of this invention also 
35 
include fragments of SEQ ID NO: 2, 3 or 4, produced by 
sequentially truncating single amino acids from the N-termi-
nus, the C-terminus or both the N- and C-termini of the 
sequences to generate shorter and shorter peptide sequences 
ultimately generating a 3 amino acid sequence. For example, 40 
SEQ ID N0:2 may be truncated by sequentially truncating 
single amino acids from theN-terminal generating shorter 
and shorter peptide sequences ultimately leaving the final 
three amino acids of the sequence Arg -Ser-Leu, or by sequen-
tially truncating single amino acids from the C-terminus of 45 
SEQ ID N0:2 ultimately leaving the final three amino acids 
30 may be water for injection, physiological saline solution, or 
artificial cerebrospinal fluid (CSF), possibly supplemented 
with other materials common in compositions for parenteral 
administration. Neutral buffered saline or saline mixed with 
serum albumin are further exemplary vehicles. 
The primary solvent in a vehicle may be either aqueous or 
non-aqueous in nature. In addition, the vehicle may contain 
other pharmaceutically-acceptable excipients for modifying 
or maintaining the pH, osmolarity, viscosity, clarity, color, 
sterility, stability, rate of dissolution, or odor of the formula-
tion. Similarly, the vehicle may contain still other pharma-
ceutically-acceptable excipients for modifYing or maintain-
ing the stability, rate of dissolution, or rate of release ofADNS 
peptide, or for promoting the absorption or penetration of 
ADNS peptide across the blood-brain barrier. Such excipients 
are those substances usually and customarily employed to 
formulate dosages for parenteral administration in either unit 
dose or multi-dose form or for direct infusion into the CSF by 
continuous or periodic infusion from an implanted pump. 
Once the therapeutic composition has been formulated, it 
of the sequence Pro-Pro-Glu, or by sequentially truncating 
one amino acid sequentially from both theN- and C-termini 
yielding ultimately a Pro-Ala-Glu (PAE) peptide sequence. 
These nested fragments may all be amidated. 50 may be stored in sterile vials as a solution, suspension, gel, 
emulsion, solid, or dehydrated or lyophilized powder. Such 
formulations may be stored either in a ready to use form or in 
a form, e.g., lyophilized, requiring reconstitution prior to 
administration. 
The term "biologically active" as used herein means that 
the ADNS peptide demonstrates similar neurotrophic prop-
erties, but not necessarily all of the same properties, and not 
necessarily to the same degree, as the GDNF protein having 
the amino acid sequence set forth in SEQ ID NO: 1. The 55 
selection of the particular neurotrophic properties of interest 
depends upon the use for which the ADNS peptide is being 
administered. The ADNS pep tides are biologically active and 
demonstrate dopaminergic neuron survival characteristics 
similar to that demonstrated by the combination of amide 60 
peptides represented by SEQ ID NOs:2, 3, or 4 using the 
evaluation of dopamine neuron survival in cultures of new-
born rat midbrain dopamine neurons as an exemplary bioas-
say, as discussed in the examples below. 
The term "substantially homologous", as used herein, 65 
means a degree of sequence homology to any one of the 
ADNS peptides having the amino acid sequences set forth in 
The optimal pharmaceutical formulation will be deter-
mined by one skilled in the art depending upon the route of 
administration and desired dosage. See for example, Reming-
ton's Pharmaceutical Sciences, 18th Ed. (1990, Mack Pub-
lishing Co., Easton, Pa. 18042) pages 1435-1712 the disclo-
sure of which is hereby incorporated by reference. The 
composition may also involve particulate preparations of 
polymeric compounds such as polylactic acid, polyglycolic 
acid, etc. or into liposomes. Hylauronic acid may also be 
used, and this may have the effect of promoting sustained 
duration in the circulation. Such compositions may influence 
the physical state, stability, rate of in vivo release, and rate of 
in vivo clearance of the present proteins and derivatives. 
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Other effective administration forms, such as parenteral 
slow-release formulations, inhalant mists, orally active for-
mulations, or suppositories, are also envisioned. Preferred 
ADNS peptide pharmaceutical compositions are formulated 
for parenteral administration, e.g., intracerebroventricular 
injection. Such parenterally administered therapeutic compo-
sitions are typically in the form of a pyrogen-free, parenter-
ally acceptable aqueous solution comprising ADNS peptide 
12 
in a pharmaceutically acceptable vehicle. One preferred 
vehicle is physiological saline. 
It is also contemplated that certain formulations containing 
ADNS peptides are to be administered orally. ADNS peptide 
which is administered in this fashion may be encapsulated 
and may be formulated with or without those carriers custom-
arily used in the compounding of solid dosage forms. The 
capsule may designed to release the active portion of the 
formulation at the point in the gastrointestinal tract when 
bioavailability is maximized and pre-systemic degradation is 
minimized. Additional excipients may be included to facili-
tate absorption of ADNS peptide. 
ate dosage for treatment involving each of the above men-
tioned formulations is routinely made by those of ordinary 
skill in the art, especially in light of the dosage information 
and assays disclosed herein. Appropriate dosages may be 
ascertained through use of the established assays for deter-
mining dosages utilized in conjunction with appropriate 
dose-response data. The final dosage regimen involved in a 
method of treating a specific condition will be determined by 
the attending physician, considering various factors which 
10 modifY the action of drugs, e.g., the age, condition, body 
weight, sex and diet of the subject, the severity of any infec-
tion, time of administration and other clinical factors. 
ADNS peptides of the present invention may also be 
15 
employed, alone or in combination with other growth factors 
in the treatment of nerve disease. For example, ADNS pep-
tides may be used in treating some forms of nerve disease in 
combination with nerve growth factor. In addition, other fac-
tors or other molecules, including chemical compositions, 
Diluents, flavorings, low melting point waxes, vegetable 
oils, lubricants, suspending agents, tablet disintegrating 
agents, and binders may also be employed. 
It is further contemplated that formulations containing 
ADNS peptides are to be administered nasally. As used 
herein, nasally administering or nasal administration includes 
administering the formulation containing ADNS to the 
mucous membranes of the nasal passage or nasal cavity of the 
patient. Formulations for nasal administration include a phar-
maceutically effective amount of the peptides prepared by 
well-known methods, to be administered, for example, as a 
nasal spray, drop, suspension, gel, ointment, cream or pow-
der. Administration of the ADNS-containing formulation 
may also take place using a nasal tampon, or nasal sponge. 
20 may be employed together withADNS peptides. In the treat-
ment of Parkinson's disease, it is contemplated that ADNS 
peptide be used by itself or in conjunction with the adminis-
tration of Levodopa, wherein the ADNS peptide would 
enhance the production of endogenous dopamine and the 
25 neuronal uptake of the increased concentration of dopamine. 
As stated above, it is also contemplated that additional 
neurotrophic or neuron nurturing factors will be useful or 
necessary to treat some neuronal cell populations or some 
types of injury or disease. Other factors that may be used in 
30 conjunction with ADNS pep tides include, but are not limited 
to: mitogens such as insulin, insulin-like growth factors, epi-
dermal growth factor, vasoactive growth factor, pituitary ade-
nylate cyclase activating polypeptide, interferon and soma-
tostatin; neurotrophic factors such as brain derived 
The ADNS peptides may be administered parenterally via 35 neurotrophic factor, neurotrophin-3, neurotrophin-4/5, neu-
rotrophin-6, insulin-like growth factor, ciliary neurotrophic 
factor, acidic and basic fibroblast growth factors, fibroblast 
growth factor-5, transforming growth factor-.beta., cocaine-
amphetamine regulated transcript (CART) and mature 
a subcutaneous, intramuscular, intravenous, transpulmonary, 
transdermal, intrathecal or intracerebral route. ADNS pep-
tides that do not cross the blood-brain barrier may be given 
directly intracerebrally or otherwise in association with other 
elements that will transport them across the barrier. It is 
preferred that the ADNS peptide is administered intracere-
broventricularly or into the brain or spinal cord subarachnoid 
space. ADNS peptides may also be administered intracere-
brally directly into the brain parenchyma. Slow-releasing 
implants in the brain containing the neurotrophic factor 45 
embedded in a biodegradable polymer matrix can also deliver 
ADNS peptides. ADNS pep tides may be administered extrac-
erebrally in a form that has been modified chemically or 
packaged so that it passes the blood-brain barrier, or it may be 
administered in connection with one or more agents capable 50 
of promoting penetration ADNS peptide across the barrier. 
For example, a conjugate ofNGF and monoclonal anti -trans-
ferrin receptor antibodies has been shown to be transported to 
the brain via binding to transferrin receptors. To achieve the 
desired dose of ADNS peptide, repeated daily or less frequent 55 
injections may be administered, or truncated ADNS peptide 
may be infused continuously or periodically from a constant-
40 GDNF; and other growth factors such as epidermal growth 
factor, leukemia inhibitory factor, interleukins, interferon, 
and colony stimulating factors; as well as molecules and 
materials which are the functional equivalents to these fac-
or programmable-flow implanted pump. The frequency of 
dosing will depend on the pharmacokinetic parameters of 
ADNS peptide as formulated, and the route of administration. 60 
Regardless of the manner of administration, the specific 
dose is typically calculated according to body weight or body 
surface area. For diseases involving the brain, the specific 
dose is typically calculated according to the approximate 
brain weight of the subject, which also may be estimated 65 
based on body weight or body surface area. Further refine-
ment of the calculations necessary to determine the appropri-
tors. 
It is envisioned that the continuous administration or sus-
tained delivery of a ADNS peptide may be advantageous for 
a given treatment. While continuous administration may be 
accomplished via a mechanical means, such as with an infu-
sion pump, it is contemplated that other modes of continuous 
or near continuous administration may be practiced. For 
example, chemical derivatization may result in sustained 
release forms of the protein which have the effect of continu-
ous presence in the blood stream, in predictable amounts, 
based on a determined dosage regimen. Thus, ADNS peptides 
of the present invention include ADNS pep tides derivatized to 
effectuate such continuous administration. 
ADNS peptide cell therapy, e.g., intracerebral implantation 
of cells producingADNS peptides, is also contemplated. This 
embodiment of the present invention may include implanting 
into subject's cells which are capable of synthesizing and 
secreting a biologically active form of the ADNS pep tides of 
the present invention. Such ADNS peptide producing-cells 
may be cells which do not normally produce a neurotrophic 
factor but have been modified to produce ADNS peptides, or 
they could be cells whose ability to produce GDNF has been 
augmented by transformation with a polynucleotide suitable 
for the expression and secretion of ADNS peptides. In order 
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to minimize a potential immunological reaction in subjects, it 
is preferred that the cells be of human origin. 
Implanted cells may be encapsulated to avoid infiltration of 
the cells into brain tissue. Human or non-human animal cells 
may be implanted in subjects in biocompatible, semi-perme- 5 
able polymeric enclosures or membranes to allow release of 
anADNS peptide, but that prevent destruction of the cells by 
the subject's immune system or by other detrimental factors 
from the surrounding tissue. Alternatively, the subject's own 
cells, transformed ex vivo to produce ADNS peptides, could 10 
be implanted directly into the subject without such encapsu-
lation. 
14 
nearly identical sequences. RRERNRQAAAANPEN-
SRGKGRR (SEQ ID NO: 15) is present in GDNF splice 
forms 1 and 2. There are some sequence variations by species, 
but consensus post-translational processing signals are main-
tained across species. FPLPAGKR (SEQ ID NO: 8) was 
found to be invariant in the available GDNF splice form 1 
sequences, but does not occur in splice forms 2 and 3. KRP-
PEAPAEDRSLGRR (SEQ ID NO: 7) scored hits in splice 
form 1, but not in the other GDNF splice forms. There are 
some sequence variations by species, but consensus process-
ing signals are maintained across species. Thus, theseADNS 
peptides are unique to mostly splice form 1 of GDNF and not 
other splice forms of the pre pro GDNF. 
Example 2 
Synthesis of ADNS Peptides 
Three peptides, designated GER9263, GER9264, and 
GDR9265 (see Table 1, below) were synthesized by Keck 
Biotechnology Resource Laboratory, Yale University New 
Haven, Conn. Synthetic peptides can be made routinely up to 
40 residues and often, depending on sequence, up to 70 resi-
The methodology for the membrane encapsulation of liv-
ing cells is familiar to those of ordinary skill in the art, and the 
preparation of the encapsulated cells and their implantation in 15 
subjects may be accomplished. See for example, U.S. Pat. 
Nos. 4,892,538; 5,011 ,472; and 5, 106,627, the disclosures of 
which are hereby incorporated by reference. A system for 
encapsulating living cells is also described in PCT Applica-
tion WO 91/10425 of Aebischer eta!., specifically incorpo- 20 
rated herein by reference. See also, PCT Application WO 
91/10470 of Aebischer et a!.; Winn et a!., Exper. Neural., 
113:322-329, 1991 ;Aebischeretal.,Exper. Neural., 111:269-
275, 1991; and Tresco eta!., ASAIO, 38:17-23, 1992, the 
disclosures of which are hereby incorporated by reference. 25 dues by this facility. All peptides were separated and purified 
on a preparative C-18 or C-4 RP-HPLC system and delivered 
as a lyophilized material. Yields for normal peptides under 40 
residues were "guaranteed" at 50 mg or more and at 90+% 
purity. Yields and purity are often higher, varying with the 
ADNS peptide gene therapy in vivo is also envisioned, 
wherein a nucleic acid sequence encoding anADNS peptide 
is introduced directly into the subject. For example, a nucleic 
acid sequence encoding an ADNS peptide is introduced into 
target cells via local injection of a nucleic acid construct with 30 
or without an appropriate delivery vector, such as an adena-
associated viral vector. Alternative viral vectors include, but 
are not limited to, retrovirus, adenovirus, herpes simplex 
virus and papilloma virus vectors. Physical transfer may be 
achieved in vivo by local injection of the desired nucleic acid 35 
construct or other appropriate delivery vector containing the 
desired nucleic acid sequence, liposome-mediated transfer, 
direct injection (naked DNA), receptor-mediated transfer 
(ligand-DNA complex), ormicroparticle bombardment (gene 
gun). It should be noted that the ADNS peptide formulations 40 
described herein may be used for veterinary as well as human 
applications and that the term "subject" should not be con-
strued in a limiting manner. In the case of veterinary applica-
tions, the dosage ranges should be the same as specified 
above. 45 
As a means of further characterizing theADNS pep tides of 
the present invention, antibodies can be developed which 
bind to theADNS peptides. One of ordinary skill in the art can 
use well-known, published procedures to obtain monoclonal 
and polyclonal antibodies, or recombinant antibodies, which 50 
specifically recognize and bind to the various ADNS pep tides 
of the present invention. 
Other aspects and advantages of the present invention will 
be understood upon consideration of the following illustrative 
examples. The examples are not to be construed in any way as 55 
limiting the scope of this invention. 
EXAMPLES 
peptide sequence and length. All peptides made in the Keck 
facility at the 0.5 mmole scale are done by tBOC chemistry 
and at a single scale range (which generates a theoretical 
crude yield of 500-1,000 mg for a 10-20 mer respectively). 
The purified peptides were characterized by analytical RP-
HPLC, amino acid analysis, and FAB mass spectroscopy. 
TABLE 1 
ADNS peptides 
Peptide Sequence 
GER9263 ERNRQAAAANPENSRGK-amide (SEQ ID NO, 2) 
GER9264 FPLPA-amide (SEQ ID NO, 3) 
GDR9265 PPEAPAEDRSL-amide (SEQ ID NO, 4) 
Example 3 
Dopaminergic Activity of ADNS Peptides in Fischer 
344 Rats 
Experiments were performed to test the effects of the three 
ADNS peptides (GER9263, GER9264, and GDR9265) on 
dopaminergic activity in normal young adult male Fischer 
344 rats. The peptides were combined in a 1:1:1 ratio. There 
were three test groups with six animals per group: vehicle 
(citrate buffer), vehicle plus 30 fll peptide mixture, and 
vehicle plus 100 flg peptide mixture. The vehicle or vehicle 
Example 1 60 plus peptide solutions were steriotaxically injected in equal 
portions into two sites each in the right substantia nigra. 
BLAST Analysis 
The three hypothetical precursor segments (RRERN-
RQAAAANPENSRGKGRR (SEQ ID NO: 15); FPLPAGKR 
(SEQ ID NO: 8); andKRPPEAPAEDRSLGRR (SEQ ID NO: 
7); see FIG. 3) were subjected to BLAST searches for short, 
One month after drug administration, the basal levels of 
dopamine and dopamine metabolites were measured by 
microdialysis in the right striatum. Potassium and amphet-
65 amine evoked release of dopamine were also evaluated. 
While basal levels of dopamine were not significantly 
altered in the striatum, average K+-evoked release of dopam-
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elevated perch, front access doors and side rear access doors 
connecting the housing cage to an adjacent activity module. 
The diet consisted of certified primate biscuits given in the 
morning (7:30AM), and supplemented daily in the afternoon 
(1:30PM) with fresh fruit or vegetables. Water was available 
ad libitum. All procedures were conducted in the Laboratory 
Animal Facilities of the 
ine increased by over 50% (FIG. 4). Average amphetamine-
evoked release was more variable, but ranged from about 30% 
for 100 to about 45% for 30 flg. While basal dopamine levels 
were about the same in all three groups, basal metabolite 
levels were elevated. As shown in FIG. 5, the major metabo-
lites 3,4-Dihydroxy-PhenylaceticAcid (DO PAC) and Homo-
vanillic Acid (HVA) were increased by about 40% (DO PAC) 
and 20-40% (HVA), depending upon the dose. 
Example 4 
ADNS Peptides and Response to CNS Delivery in an 
Aged Rhesus Monkey 
University of Kentucky, which are fully accredited by the 
Association for Assessment and Accreditation of Laboratory 
10 Animal Care. Veterinarians skilled in the health care and 
maintenance of nonhuman primates supervised all animal 
care. 
MRI Imaging: 
Magnetic resonance images (MRI) were obtained on a 
1.5T clinical imager (Siemens Magnetom Vision) using a 
standard cross polarized extremity coil. After being sedated 
with ketamine hydrochloride ( -20 mg/kg; i.m.) plus atropine 
sulfate (-0.04 mg/kg; i.m.), the animal was anesthetized with 
A study was performed demonstrating that a mixture of 15 
three ADNS peptides (GER9263, GER9264, and GDR9265 
combined in a 1: 1:1 ratio) exerts pharmacological effects on 
CNS nigra! dopamine neurons in an aged rhesus monkey 
similar to those produced by GDNF. Marked increases of 
68-125% in stimulus-evoked dopamine release were mea-
sured in the putamen by in vivo microdialysis. Motor speed, 
20 sodium pentobarbital ( -10 mg/kg; i.v.) and imaged to provide 
stereotaxic coordinates for peptide delivery. The animal's 
head was positioned in the extremity coil using an MRI com-
patible stereotaxic head frame. This frame kept the animal's 
head level and immobilized at the center of the radio fre-
as measured in fine motor hand movements, increased by up 
to 58%, into the range of young adult monkeys. General body 
movements increase by 38%, indicating much higher activity 
levels. The effects from unilateral treatment were long -lasting 25 
(for at least one month) and bilateral, similar to those result-
ing from GDNF treatment. Histopathological analysis of the 
injection sites in the substantia nigra revealed only mild, 
circumscribed pathology from the peptide injections. The 
pharmacological effects of ADNS peptides on upregulating 30 
nigrostriatal dopamine system functions are extraordinary 
and suggest their potential therapeutic use for the treatment of 
Parkinson's disease and age-associated movement dysfunc-
tions. 
The ADNS pep tides tested in this Example are three ami- 35 
dated peptides predicted to exert potent biological effects 
similar to those of Glial Cell Line-Derived Neurotrophic Fac-
tor (GDNF). The effects ofGDNF on CNS dopamine neurons 
fall generally into three categories: pharmacological upregu-
lation of dopaminergic activity, neuronal regeneration and 40 
neuroprotection. This study was designed to assess the phar-
macological effects of ADNS peptides on substantia nigra 
dopamine neurons in the nonhuman primate brain. It was 
previously shown that CNS delivery of GDNF increases 
stimulus-evoked dopamine release in aged rhesus monkeys 45 
(Grondin et a!., 2003). In addition, behavioral correlates of 
increased dopaminergic activity were recorded in these ani-
mals, improved motor functions and increased motor speed. 
The present study was a case report on one aged monkey that 
received a 100 ng injection of ADNS peptides into the sub- 50 
stantia nigra of the brain and was followed for 30 days. Motor 
speed was measured weekly using an automated movement 
analysis panel (MAP) and Etho Vision, a video tracking pro-
gram. Movement features were rated weekly using a nonhu-
man primate clinical rating scale (Zhang, Z. eta!., J Geron- 55 
tology: Biol. Sci. 55A:B473-B480, (2000)). Stimulus-evoked 
dopamine release was analyzed by microdialysis at the 30 day 
time point. The animal was then euthanized and the brain 
recovered for histopathological analysis. 
quency coil using ear and mouth bars. An initial set of coor-
dinates was taken using the earbars, toothbar and a zeroing 
bar targeted to the gum line between the two upper middle 
incisors to allow replication any time the animal was replaced 
in the stereotaxic apparatus. 
The coil/frame assembly was then positioned to place the 
animal's head at magnet isocenter. Sets of T1-weighted 
3D-FLASH images were collected for determination of the 
brain coordinates (TR/TE=22/9 ms; FA=35°; FOV =96x96x 
90 mm; Matrix=128x128x90; Nacq=2; TA=6 min 48 sec). 
All images were acquired as coronal slices relative to the 
brain. Antero-posterior, lateral and vertical coordinates for 
stereotaxic surgery were derived from the T1-weighted coro-
nal brain images. The interaural line was identified on the 
scans by modified earbars containing Vitamin E. This pro-
vided a precise reference-point, which allowed for anteropos-
terior measurements to the target. Lateral measurements were 
determined by measuring the distance from the sagittal sinus/ 
third ventricle to the target site. Vertical measurements were 
determined from the surface of the brain to the target at the 
lateral coordinate. 
Surgery: 
Following sedation with ketamine hydrochloride (-20 
mg/kg; i.m.) plus atropine sulfate (-0.04 mg/kg; i.m.), the 
animal was intubated via the orotracheal method and intrave-
nous lines secured. Then, the animal was anesthetized with 
isoflurane (1-3%) and placed in an MRI compatible Kopf 
stereotaxic apparatus in a ventral-lateral position as per the 
coordinates previously (see Anatomical MRI above). The 
animal was maintained on a heated blanket and had cardiac 
and respiratory parameters monitored during the procedure, 
which was carried out using sterile field conditions. Coordi-
nates for peptide injections were determined by MRI prior to 
the surgery as described above. After being shaved, the scalp 
area was cleaned using antiseptic procedures with sterile 4x4 
Methods Used for Studying ADNS Peptides Animal: 
A thirty-four year old female rhesus monkey (ID# NJ05) 
weighing 7 kg was used. The animal was diagnosed as having 
60 sponges soaked in Betadine® surgical scrub followed by 70% 
isopropyl alcohol. This procedure was repeated. After the 
alcohol dried, Betadine® prep was applied and the animal 
was covered with sterile drapes. Then, an incision was made an inoperable mammary tumor, with the attending veterinar-
ian suggesting that the monkey be placed in a terminal study 
and euthanized for humanitarian reasons. The animal was 65 
maintained on a 12-hour light/12-hour dark cycle and housed 
individually in a cage measuring 9 square feet, with an 
through the scalp and the skin and muscles overlying the skull 
were reflected. Small holes were drilled in the skull directly 
over the target area. The overlying meninges were removed to 
expose the surface of the brain. 
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A 1.0 mg/ml concentration of the three-peptide mixture in 
citrate buffer was used. It was sterilized by filtration prior to 
injection Using MRI-guided procedures, a 27 G needle 
coupled to a Hamilton syringe containing 100 fll (i.e. 100 flg) 
of the peptide mixture was lowered in the right rostral SNc 
(AP: 11, L: 5, DV: 30 from surface of the brain).A volume of 
50 fll was delivered using a nanopump at a rate of This was 
followed by a 20 min waiting period before retracting the 
needle out of the brain (1 mm/min). The needle/syringe 
assembly was then moved 1 mm caudally and 0.5 mm later-
ally and lowered into the more caudal SNc (AP: 10, L: 5.5, 
DV: 29 from surface of the brain). This was followed by a 20 
min waiting period before retracting the needle out of the 
brain (1 mm/min). After completion of the injections, the 
scalp incision was sutured over the exposed areas per normal 
procedures and the animal was given an analgesic (buprenor-
phine, 0.01 mg/kg, i.m.). Vital signs were monitored until the 
animal awakened, at which point the animal was covered with 
warm blankets and taken back to its cage and monitored until 
it was ambulatory. 
Behavioral Tests: 
To assess changes in motor functions, the animal was vid-
eotaped prior to injecting the peptide mixture, and weekly 
after the injection for four weeks. The videotaping cage mea-
sured 28 in Wx32 inHx32 inD, had a white background wall 
and a clear Lexan window permitting videotaping. The vid-
eotaping cage was illuminated by two 48 in-long fluorescent 
lights located 30 in above. Water (via a cage attached bottle) 
was available ad libitum throughout the session. The animal 
was fed fruit or vegetables after completion of data acquisi-
tion and upon return to its home cage. 
18 
outline of the cage in the video image, in addition, two zones 
were outlined, so that the overall activity measured in the 
entire cage could be analyzed in terms of vertical (top half) or 
horizontal (bottom half) activity. As described above, the 
animal was videotaped for 60-minute periods, pre- and post-
treatment, and the video tracks were analyzed at a rate of 
6-sample/sec. For every sample, the cage was scanned and the 
position of the tracked animal was determined by using a gray 
scale detection method (brightness). This entails calibrating 
10 the software to distinguish the dark-colored animal from the 
background, which is then defined as all other pixels. The 
back wall of the cage was painted white to provide a back-
ground with a maximum degree of contrast with the dark-
colored primate. This automated method relies on determin-
15 ing the position of the center of mass of the animal in the cage, 
and the resultant x-y coordinates extracted as a function of 
time are used for calculating the movement pattern during the 
observation period. These coordinates were subsequently 
related to actual spatial measures by calibrating the software 
20 to the dimension (width) of the cage, the distance traveled by 
the animal were calculated in centimeters instead of pixels. 
Movement Analysis Panel (MAP): 
In addition, fine/hand motor movement times in retrieving 
food items from a platform level placed in a receptacle cham-
25 ber were measured using an automated clear Lexan MAP 
attached to the door opening of the home cage (see Gash, D. 
M. eta!. J. Neurosci Methods 89:111-117, (1999) and Zhang 
eta!., 2000). The receptacle chamber is divided into left and 
right halves, and is accessible on each side through two por-
30 tals (arnlhole portal and receptacle portal). Movement times 
were measured by arrays of three photodiodes around each 
portal that automatically relayed to the computer when one or 
more beams were broken by passage of the monkey's arm/ 
hand. Testing was conducted in the afternoon, prior to inject-
Beginning at 1 PM, a technician entered the room and 
placed small food items (e.g. gummy bears) on the ledge of 
the cage to elicit the animal to stand-up and reach out for the 
food. Then, the animal was videotaped for 30 minutes with no 
one in the room. Following this 30-minute videotaping 
period, the technician re-entered the room, stopped recording 
and attached a non-wired version of the monkey Movement 
Analysis Panel (MAP, see below) to the doorway of the cage 
for a hand retrieval test. Five to six preferred small food items 40 
(e.g. miniature marshmallows) were placed on each side of 
the panel. The animals was given 10 minutes (default time) to 
retrieve the food items, at which point the tester re-entered the 
room and stopped recording. This portion of the session was 
videotaped, with a focus on the hands. Starting at 2 PM, the 
same procedures described above were repeated. At the end of 
the testing session, the animal was returned to its home cage. 
35 ing the peptide mixture, and weekly thereafter for four weeks. 
Fresh fruit and vegetables were given to the animal after 
completion of the testing session. A day's testing session 
consisted of twelve trials, six on each side alternating 
between the right and left hand. 
Microdialysis Studies: 
The animal underwent bilateral putamenal microdialysis 
one month post ADNS peptide injection. Using the method 
described below, in vivo microdialysis procedures had also 
been conducted previously in the right striatum of the same 
45 animal (date: Feb. 10, 2004; coordinates: AP:20.5 mm, 
L:10.2 mm, DV from cortex:21 mm). 
Following normal MRI-guided stereotactic procedures 
(see Surgical procedures for ADNS peptide injection), cus-
tom-made CMA/11 dialysis probes with a membrane length 
As described above, standardized videotaping procedures 
were conducted pre- and post-treatment. Behavioral param-
eters associated with motor function were scored from coded 
videotapes from 0 (normal) to 3 (severe disability) in the 
following categories: rigidity, bradykinesia, posture, balance, 
tremor, and hand dexterity (see Zhang eta!., 2000). Rigidity 
is defined as a decrease in limb extension and/or use. Motor 
dysfunctions were rated in half-point increments by an expe-
rienced rater. 
Distance traveled (em) was quantified from 8-mm video-
tapes (SONY P6-120MPL) using a commercially available 
video tracking system EthoVision Pro (version 2.3, Noldus 
Information Technology, Asheville, N.C.) coupled to a 
SONY Digital 8 video cassette recorder. This system runs on 
a Pentium based computer with a frame grabber card (PI-
COLO, Belgium), so that the analog video signal coming 
from the video cassette recorder is digitized and transferred to 
the computer. A window on the computer screen directly 
displays the video image, and the boundaries within which 
tracking took place were defined by accurately tracing the 
50 of 3 mm and diameter of 0.24 mm (CMA Microdialysis, 
North Chelmsford, Mass.) were positioned (1 mm/min) bilat-
erally in the putamen (AP:20 mm, L:10.5 mm, DV from 
cortex:20 mm). Probes were perfused continuously at a rate 
of 1.2 fll/min with artificial cerebrospinal fluid using a com-
55 puterized multisyringe pump (World Precision Instruments). 
Microdialysate fractions were collected at 30 min intervals. 
Following a 1-hour application of artificial cerebrospinal 
fluid to collect baseline fractions, excess potassium (1 00 mM 
KCl, 47.7 mM NaCl) was then included in the perfusate for a 
60 single 30-min fraction (t0-t30). Two hours later 250 f.LM 
amphetamine was included in the perfusate for a single 
30-mM fraction (t1-t150). Three additional fractions were col-
lected after discontinuing amphetamine administration (t180-
t240). The incision was then closed as per normal surgical 
65 procedures. Microdialysate fractions were analyzed using 
standard high performance liquid chromatography proce-
dures coupled with electrochemical detection. 
US 9,402,875 B2 
19 20 
Tissue Collection Procedures: putamen ofNJ05 using microdialysis to collect samples for 
neurochemical analysis. FIG. 7A shows the first recordings 
made Feb. 10, 2004, several years prior to the ADNS peptide 
study. In aging monkeys, dopamine evoked release of dopam-
ine to K+ and d-AMPH normally decreases with increasing 
age. FIG. 7B shows the second set of recordings made thirty 
days after ADNS peptide injections into the right substantia 
nigra onApr. 27,2006. K+ evokedreleasewas increased from 
the 2004 reading from 36.5 nM to 82 nM. D-AMPH evoked 
Tissue biopsies were collected for possible future use. At 
the end of the dialysis session, the animal was immediately 
euthanized. The deeply anesthetized animal (2 ml pentobar-
bital, i.v.) was transcardially perfused with heparinized ice- 5 
cold saline (6 L). Then, the brain was removed quickly, and 
dropped into a container of cold saline, which was placed on 
wet ice and taken back to the laboratory. Using an ice-cold 
mold, the brain was sectioned into 4-mm coronal slabs, rostral 
of the midbrain. 10 release of dopamine increased from 74 nM to 125 nM after 
ADNS peptide administration. Thus, in comparison to mea-
surements recorded under similar conditions two years earlier 
in the same animal, potassium-evoked overflow of dopamine 
was increased by 125% at 30 days postADNS peptide admin-
Multiple tissue punches were taken bilaterally from frozen 
4-mm thick coronal tissue sections using a 14G biopsy needle 
in the caudate nucleus (n= 18 per side, tissue slabs #3, #4 and 
#5), putamen (n=18 per side, tissue slabs #4, #5, #6), nucleus 
accumbens (n=7 per side, tissue slabs #3 and #4) and globus 
pallidus (n=5 per side, tissue slabs #6). Separate needles were 
used for the right and left (green tape) hemisphere. All 
punches were rapidly transferred to pre-weighed storage 
tubes, weighed once more, and stored at -80° C. Pictures of 
the punched slabs were taken to document the punching pat-
tern, and then they were stored at -80° C. 
The midbrain was taken out as a block, which included the 
cerebellum, and post-fixed for quantitative immunocy-
tochemistry of substanita nigra dopamine neurons and TH+ 
processes. To do so, the midbrain was immediately immersed 
in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) 
at 4 o C. for three days and transferred to 15% sucrose solution 
until saturated for sectioning. Then, a series of 40 f.tm-thick 
coronal sections were cut on a frozen sliding microtome. One 
out of every 12th adjacent sections was processed for cresyl 
violet (Nissl) and hematoxylin and eosin (H & E) staining. 
Also, !/12th adjacent sections were processed for the follow-
ing staining: a) 1:1000 mouse anti-glia fibrillary acidic pro-
tein (GFAP) antibody for astrocytes, b) 1:200 mouse anti-
HLA-DR antibody for reactive microglia, and c) 1:1000 
mouse anti-tyrosine hydroxylase (TH) antibody for dopam-
inergic neurons (see Ai eta!., 2003). 
Effects of ADNS Peptides on an Aged Rhesus Money 
The animal recovered without problems from peptide 
delivery into the right substantia nigra. No clinically observ-
able abnormal behaviors (e.g. auto-mutilation, stereotypic 
movements, dyskinesia, vomiting) were noted throughout the 
30-day study. 
15 istration (from 36.5 nM to 82 nM). Similarly, amphetamine-
induced overflow of dopamine was increased by 68% com-
pared to measurements recorded two years earlier (from 74 
nM to 125 nM). 
Basal levels of dopamine and dopamine metabolites in the 
20 striatum were determined from measurements in the microdi-
alysates prior to potassium and amphetamine stimulation. 
Basal dialysate levels of dopamine and HVA showed small 
changes from the baseline levels two years earlier (Table 2). 
However, basal levels of extracellular DO PAC were increased 
25 by 230% at thirty days post peptide injection compared to the 
earlier baseline measures (Table 3). 
The histopathological response to the injection of peptides 
in the nigra! region was mild (see FIGS. S and 9). In FIG. S, 
one of the injection sites (arrow) is shown using standard 
30 histochemical techniques for Nissl staining and hematoxylin 
and eosin (H & E) staining. Immunostaining was conducted 
to assess the response of astrocytes (GFAP positive cells) and 
microglia (HLA-DR positive cells) to the injections. In 
FIGS. SA and B, this injection site (arrow) was just dorsal 
35 to the substantia nigra, pars compacta (SNc ). While there is an 
evident response at the injection site and a smaller satellite 
area (*) of reactivity dorsal to the main area, the injury 
response is very circumscribed. FIG. SC shows that reactive 
astrocytosis, as assessed by GFAP positive reactivity around 
40 the needle track, is minimal, approximately that expected 
from a needle tract injury alone. In FIGS. SD and E, the injury 
response appears similar using H & E to that seen with Nissl. 
The injury response is localized and does not seem to involve 
adjacent cells. Reactive microglia (HLA-DR +cells) are a As described above, standardized videotaping procedures 
were conducted pre- and post-treatment to assess changes in 
motor functions from coded videotapes. Prior to injecting the 
three-peptide mixture into the right substantia nigra, the ani-
mal was given a cumulative score of3.25 points on the rating 
scale (See Table 2). Although the effect was variable, this 
score improved (the lower the score, the better the movement 
functions) by over 30% (i.e. 1 point) by the fourth week of the 
study. Similarly, distance traveled (em) measured over 
weekly 60-minute periods using the automated video-track-
ing system (EthoVision) improved up to 38% by the fourth 
week post treatment versus baseline locomotor activity (from 55 
7064 em to 9780 em). Last but not least, MAP performance 
times for left hand motor were 56% faster by week four post 
peptide treatment (from 0.81 sec to 0.36 sec). Right hand 
performance times were already faster than the left pre-pep-
tide treatment. They further improved in the 4 weeks post-
treatment, with performance times 14% faster (from 0.36 sec 
45 prominent constituent of the injury response (arrow and *, 
FIG. SF). (In FIG. S, Cerebral peduncle=CP; Substantia nigra 
reticulatia=SNr; Ventral Tegmental Area=VTA. Scale bars 
are included in each photomicrograph.) The injection site 
showed reactive cells in an area about 200 f.LM wide by 400 
50 f.tm long in Nissl-stained and H & E-stained sections (FIG. S 
A, B, D and E). The response consisted of activated microglia 
(HLA-DR positive cells, FIG. SF). The absence of pro-
nounced GFAP immunostaining (FIG. S) indicated that the 
injection did not stimulate a glial reaction. 
The substantia nigra pars compacta (SNc) containing the 
population of dopamine neurons that degenerates in Parkin-
son's disease is evaluated in the series of photomicrographs 
set forth in FIG. 9. In FIG. 9A, Nissl-rich neurons (arrow-
heads) adjacent to the peptide injection site(*) appear normal 
60 with prominent nuclei evident in the nucleus of some cells. 
Nissl staining corresponds to the presence of rough endoplas-
mic reticulum in the cytoplasm and indicates cells actively 
synthesizing protein. The H & E stained section in FIG. 9B 
also shows neurons with normal features (arrowheads) adja-
to 0.31 sec). In vivo microdialysis was used to investigate the 
dynamics of dopamine release in the basal ganglia. Measure-
ments were carried out in the right putamen four weeks post 
peptide treatment (see FIGS. 7A and B). In particular, FIG. 7 
shows the results of potassium (K+) and d-amphetamine 
( d-AMPH) evoked release of dopamine measured in the right 
65 cent to the injection site(*). FIG. 9C shows that there are only 
a few scattered activated microglia (arrowheads showing 
HLA-DR positive cells) in the SNc. Large numbers would 
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indicate ongoing pathological processes. Tyrosine hydroxy-
lase (TH) is the rate-limiting enzyme in dopamine synthesis. 
The TH positive cells shown in FIG. 9D are dopamine neu-
rons. Their size and exuberant expression of TH positive 
processes are indicative ofhealthy, active cells. Scale bars are 
included in each photomicrograph. Dopamine neurons in the 
substantia nigra appeared to be normal (FIG. 9). Tyrosine 
hydroxylase immunostaining (FIG. 9D) revealed large 
dopamine neuron perikarya (cell bodies) with extensive neu-
ritic processes. Along with the Nissl and H & E stained 
sections (FIGS. 9 A and B), the nigra! cells showed features 
characteristic of healthy neurons. A few activated microglia 
(HLA-DR positive cells, FIG. 9C) were present in the nigra! 
region, a typical feature of this brain region in healthy aged 
monkeys. Large numbers of activated microglia would be 15 
indicative of an ongoing disease process. The subject in this 
study was a very old rhesus monkey, 34 years old. One year 
for a rhesus monkey is roughly equivalent to three years of 
human life, making this animal equivalent to a 100 year old 
person. The monkey was used in this study because it had a 20 
terminal disease, mammary cancer. The closest comparable 
monkeys in an earlier study treated with GDNF were 22-24 
years old (Grondin eta!., 2003). They received infusions of 
GDNF into the brain for 24 weeks while NJ05 had a single 
injection of anADNS peptide mixture and was monitored for 25 
one month. Despite the differences, many of the responses 
were comparable to those seen to GDNF. NJOS motor per-
formance times on the MAP improved within four weeks on 
both the right (14%) and left (56%) sides. The improved 
motor speeds approached the speeds of aged monkeys receiv- 30 
ing GDNF and those of normal young adult animals. Consis-
tent with increased motor speed, general locomotor activity 
was increased by 38% by four weeks of treatment in NJ05. 
There were neurochemical changes in NJ05's brain along 
with the behavioral improvements. Both potassium- and 35 
amphetamine-evoked release were increased (125% and 
68%, respectively) in the putamen in comparison to pretreat-
ment levels. This was similar to the increased evoked release 
22 
TABLE 2-continued 
Changes in motor functions post ADNS peptides delivery into the 
right substantia nigra. 
Disability Locomotor Left Map Right MAP 
Score Activity Times times 
(pts)/% (em)/% (sec)/% (sec)/% 
Treatment baseline baseline baseline baseline 
Week3 2.50/-23% 6368/-10% 0.75/-7% 0.34/-6% 
Week4 2.25/-31% 9780/+38% 0.36/-56% 0.31/-14% 
The reduction in the disability score means that the motor functions such as walking and 
balance were improving. The locomotor activity level increases by week four also reflect that 
the animal was increasing the time and distance in walking. The Movement Analysis Panel 
(M:AP) scores demonstrate much faster hand fine motor movements by week 4 after treat-
ment. 
TABLE3 
Changes in basal dialysate levels of dopamine and dopamine 
metabolites in the right putamen, 30 days post ADNS peptide 
delivery into the right substantia nigra. 
Hemisphere 
Pre-peptides 
Post-peptides 
Dopamine (nM) 
5.6 
4.9 
HVA(nM) 
5033 
4191 
DOPAC (nM) 
127 
419 
The large increase in levels of the dopamine metabolite DOPAC indicate increase dopam-
inergic activity. As the enzyme (monoamine oxidase B) for metabolizing dopamine to 
DOPAC is on the outer membrane of mitochondria, it also reflects either more active 
mitochondria and increased numbers of mitochondria. 
Example 5 
Materials and Methods 
The following materials and methods were used in the 
following examples. 
Materials: Unless otherwise stated, all cell reagents and 
assays were purchased from Invitrogen. All other materials 
and chemicals are reagent grade. DNSP-17 (GER 9263), 
DNSP-5 (GER 9264), DNSF'-11 (GER 9265), and Biotiny-
of dopamine in response to the same stimulants in aged rhesus 
monkeys treated with GDNF (Grondin et a!., 2003). Basal 
dialysate levels of dopamine, HVA and DO PAC showed high 
variability, but were not significantly changed in aged GDNF 
recipients. NJ05's basal dopamine and dopamine metabolite 
levels were in the same range as the GDNF and vehicle-
treated old animals. The only dramatic change seen in this 
animal was in DO PAC levels, which increased over three-fold 
post ADNS peptide treatment. The significance of this 
response is that it reflects higher levels of dopamine metabo-
lism in the striatum. 
40 Ia ted DNSP-11: DNSP-17 (sequence: ERNRQAAAAN-
PENSRGK-amide (SEQ ID NO: 2)), DNSP-5 (sequence: 
Histopathology was much less extensive than the damage 
in the same region from the infusion ofGDNF (see Gash, D. 
M. eta!., Ann Neural 58(2):224-33 (2005)). The dopamine 
neurons in the substantia nigra appeared healthy, with numer-
ous neuritic processes. 
TABLE2 
Changes in motor functions post ADNS peptides delivery into the 
right substantia nigra. 
Disability Locomotor Left Map Right MAP 
Score Activity Times times 
(pts)/% (em)/% (sec)/% (sec)/% 
Treatment baseline baseline baseline baseline 
Baseline 3.25 7064 0.81 0.36 
Week! 2.00/-38% 8422/+19% 0.86/+6% 0.45/+25% 
Week2 2.00/-38% 7136/+1% 1.09/+35% 0.39/+8% 
FPLPA-amide (SEQ ID NO: 3)): DNSP-11 (sequence: 
PPEAPAEDRSL-amide (SEQ ID NO: 4)) and biotinylated 
DNSP-11 (bDNSP-11; sequence: biotin-PPEAPAEDRSL-
45 amide (SEQ ID NO: 4)) were synthesized and RP-HPLC 
purified to >98% by AC Scientific (Duluth, Ga.) and the W.M. 
Keck Foundation Biotechnology Resource Laboratory at Yale 
University. Peptides were characterized for purity and correct 
sequence by MALDI-TOF LC-MS and Edman degradation. 
50 DNSP-11 was determined to be stable, in vitro, at a variety of 
experimentally relevant concentrations and temperatures, 
including 37° C. in sterile pH 5 citrate buffer for 31 days. 
Tissue preparation for DNSP-11 Staining in Substantia 
Nigra at Postnatal Day (PN1 0): Tissue was prepared from SD 
55 pups. Brains were rinsed in Dulbecco's Phosphate Buffered 
Saline (DPBS, Gibco ), and submerged in 4% paraformalde-
hyde pH 7.4 for 48 hours. Following submersion in 30% 
sucrose, brains were sectioned coronally (40 f.tm) and stored 
60 
65 
in cryoprotectant solution at -70° C. until processed for 
immunohistochemistry. 
DNSP-11 treatment of Mesencephalic Cells: Timed preg-
nant SD rats (Harlan) were used to obtain the ventral mesen-
cephalon from E14 fetuses. The dissected tissue was col-
lected in cold Neurobasal™ medium and rinsed twice with 
cold Dulbecco's PBS. The cells were chemically (TrypLE®) 
and mechanically dissociated to yield a single cell suspen-
sion. The solution was centrifuged at 169 g for 6 minutes and 
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the pellet was resuspended in Dulbecco's Modified Eagle 
Medium (DMEM). Cells were plated in a 25 f.LL micro-island 
at a density of 4000 cells/f.LL on poly-D-lysine coated 24-well 
plates (Sigma). Following adherence, cells were supple-
mented with warm NEUROBASAL™ media containing 2 5 
mM glutamine, 1 xN 2 , and 100 units of penicillin/streptomy-
cin. Neurotrophic compounds were added at each media addi-
tion, including initial plating and DIY 2. A dose response of 
the peptides (0.03 ng to 10 ng/mL) was added to a 24-well 
plate following media supplementation. 10 
MN9D Cell Cultures: The MN9D cell line has been 
24 
1190. CMA 11 microdialysis probes with a 4.0 mm mem-
brane length and 6 kDa molecular weight cut-off were placed 
within the rat striatum. 
Unilateral 6-0HDA Lesions: The 6-0HDA solution was 
delivered to two injection sites along the medial forebrain 
bundle (MFB) using a protocol described by Lundblad eta!. 
(2002) Eur. J. Neurosci. 15:120-132. Five weeks after the 
unilateral 6-0HDA MFB lesion procedure, animals were 
grouped based on apomorphine (0.05 mg/kg, s.c.)-induced 
rotational behaviour: Animals with >300 rotations per 60 
minutes were selected. Lesioned animals received 5 vit of 
either a 20 flg/vd, DNSP-11 solution or citrate buffer vehicle 
solution in a manner similar to infusion delivery in normal 
described by Choi (1991)BrainRes. 552:67-76 and was a gift 
from Michael Zigmond. Cells were cultured in DMEM 
supplemented with 10% Fetal Bovine Serum (FBS, 
Hyclone), 50 U/mL penicillin and streptomycin. For experi-
ments, the cells were plated on 24-well poly-D-lysine in 
DMEM with 1% (v/v) penicillin-streptomycin. The cells 
were grown at 37° C. in 5% C02 . 
15 
animals. 
Caspase-3 Activity Assay in MN9D Cells: MN9D cells 20 
were plated to 100,000 cells/well. Cell cultures were exposed 
to DNSP-11 (1 ng/mL) orbufferfor 1 hour prior to 15 min 100 
f.LM 6-0HDA exposure. Caspase-3 activity was monitored 
after 3 hours by fluorescence (excitation/emission 496/520 
nm) using the Enz Chek Caspase-3 kit. Protein levels oflysed 25 
cells were measured by BCA assay (BioRad) and normalized 
for every experiment. Data expressed as % control and 
repeated a minimum of3 times. 
Terminal dUTP Nick-End Labeling (TUNEL) Assay in 
MN9D Cells: After treatment with DNSP-11, MN9D cells 30 
were fixed and labelled to assess degenerative nuclear 
changes as indicated by the extent of high-molecular weight 
DNA strand breaks. DNA fragmentation was detected by 
using steptavidin-horseradish peroxidise conjugate followed 
by the substrate diaminobenzidine (DAB) generating a col- 35 
ored precipitate. Ratios between apoptotic and total cells 
were determined (4 random fields/well; 4 wells/ group). 
Experiments were repeated 3 times. 
Double Fluorescent Immunostaining of DNSP-11: Float-
ing sections were pretreated with 0.2% H20 2 in potassium 40 
phosphate buffered saline (KPBS) for 10 minutes and 
blocked with 4% normal goat serum in KPBS for 1 hour. 
Then, sections were incubated overnight with both rabbit 
anti-hDNSP-11 antibody (1:2000, Alpha Diagnostic) and 
mouse anti-TH antibody (1:1000, Chemicon) in KPBS at 4° 45 
C. After washing with KPBS, the sections were incubated 
with Alexa-488 conjugated goat anti-rabbit IgG (1:500, 
Molecular Probes) and Alexa-568 conjugated goat anti-
mouse IgG (1:500, Molecular Probes) for 3 hours. The sec-
tions were washed extensively and visualized with a Nikon 50 
fluorescence microscope. 
Animals and Surgical Procedures for Normal and 
6-0HDA-Lesioned Rats: Fischer 344 (F344) rats were used 
for all experiments and maintained under a 12 hour light/ dark 
cycle with food and water provided ad libitum. All procedures 55 
were approved by the University of Kentucky Institutional 
Animal Care and Use Committee following AAALACI 
guidelines. 
Infusion Delivery ofDNSP-11 or Vehicle: Isoflurane anes-
thetized (1.5-2.5%) F344 rats received 5 fll of 6 flg/flL DNSP- 60 
11 solution or citrate buffer vehicle solution in a blinded 
manner. Treatment was delivered to the nigra! cell bodies 
using the same stereotaxic coordinates and protocol for solu-
tion delivery as in studies of GDNF. 
Neurochemical Content of Tissue: Lesioned animals were 
euthanized 5 weeks after DNSP-11 or vehicle infusion. The 
brains were sliced into 1 mm thick sections. Tissue punches 
were taken from the striatum and the substantia nigra and they 
were weighed, quick frozen and stored at -70° C. until they 
were assayed by high performance liquid chromatography 
with electrochemical detection as described by Hall et a!. 
(1989) LC/GC-Mag Sep Sci 7:258-265. 
Apomorphine-induced Rotational Behavior Testing: 
Lesion severity was assessed prior to DNSP-11 treatment 
using apomorphine (0.05 mg/kg, s.c.)-induced rotational 
behavior. Beginning one week after DNSP-11 treatment, apo-
morphine-induced rotational behavior was monitored weekly 
for four weeks as described by Hoffer eta!. (1994) Neurosci 
Lett. 182:107-111 (1994) andHudsonet a!. (1993)BrainRes. 
626:167-174 (1993). 
DNSP-11 Pull-down analysis: The F344 substantia nigra 
was homogenized in homogenization buffer (modified from 
York eta!. (2005)FASEDJ.19: 1202-4with20mMHEPES, 
pH 7 .4) and cytosolic fraction (supernatant) collected after 30 
minutes at 100,000 g. 50 flg ofbDNSP-11 was incubated with 
fraction for 15 minutes on ice. Sample was added to strepta-
vidin magnetic beads (New England Biolabs), pelleted, and 
washed four times in homogenization buffer. Bound proteins 
were eluted by Solubilization/Rehydration Solution (7 M 
Urea, 2 M Thiourea, 50 mM DTT, 4% CHAPS, 1% NP-40, 
0.2% Carrier ampholytes, 0.0002% Bromophenol blue), and 
analyzed by 2D-PAGE and MALDI-TOF MS. 
Example 6 
Neurobiological Actions of DNSP-11 
GDNF is endogenously produced as a pre-proprotein of 
211 amino acids that is processed and secreted as a mature 
homodimer with a molecular weight of 32-42 kDa. The fol-
lowing examples illustrate the neurobiological actions of 
dopamine neuron stimulating peptide-11 (DNSP-11 ), an 
11-merpeptide that has been independently predicted to be an 
endopeptidase cleavage product from the human GDNF 
prosequence (FIG. lOA). 
FIGS. lOA and lOB illustrate the sequence origin and 
homology ofDNSP-11. DNSP-11 (filled) is an 11 amino acid 
sequence present in the proprotein region of the 211 amino 
acid human preproGDNF sequence. After cleavage of the 
pre-signal sequence (shaded), DNSP-11 is predicted to be 
cleaved from the proprotein at flanking dibasic cleavage sites 
by endopeptidases. Further predicted processing yields the 
C-terminal amidated peptide. The N-terminal (striped) and 
Reverse Microdialysis: Reverse in vivo microdialysis was 
accomplished using methods and brain coordinates described 
by Hebert eta!. (1996)J Pharmacal. Exper. Ther. 279:1181-
65 C-terminal (checkered) proprotein fragments and mature 
GDNF (open) protein are shown. The sequence figure is not 
drawn to scale to highlight the processing of DNSP-11. 
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DNSP-11 (FIG. lOB) shows high sequence homology to the 
rat and mouse proGDNF sequences suggesting a conserved 
function. 
In vivo expression of the DNSP-11 sequence in the sub-
stanta nigra of the ventral mesencephalon from SD pups at 5 
postnatal day 10 (PN10) was examined. Immunostaining for 
DNSP-11 in the mesencephalon of the SD pups indicated that 
the sequence is present endogenously in tyrosine hydroxylase 
positive (TH +) dopaminergic neurons of the substantia nigra 
at PN10 ns (yellow). The DNSP-11 sequence colocalized 10 
within dopaminergic cell bodies at PNIO. 
The neurotrophic effects of DNSP-11 were studied by 
comparing its effects to the well-known effects ofGDNF on 
the maintenance of primary mesencephalic cell cultures from 
E14 SD rat embryos. E14 SD rat embryo primary dopamin- 15 
ergic neurons from the ventral mesencephalon were grown 
for 5 days in vitro and neurotrophic molecules were added at 
each media change, including initial plating and day 2. GDNF 
(FIG. llA, open bars) and DNSP-11 (FIG. llA, solid bars) 
were added at various concentrations (0.03, 0.1, 1.0 and 10 20 
ng/ml; 1 OmM citrate buffer+ 150 mM NaCl, pH 5) and were 
seen to significantly increase TH+ neuron counts ( +SD; one-
way AN OVA withNewman-Keuls post hoc analysis, *p<0.05 
and** p<O.Ol) Specifically, DNSP-11 increased cell survival 
75% over citrate buffer control, as indicated by immunocy- 25 
tochemical staining of TH+ neurons 5 days in vitro (FIG. 
llA). Furthermore, DNSP-11 significantly enhanced mor-
phological changes consistent with a neurotrophic molecule 
including: neurite length, total number of branches, and 
increased total number of TH+ cells (Table 4; FIG. llB). 30 
These effects were similar to those observed for GDNF in 
26 
6-0HDA-induced toxicity in the dopaminergic cell line, 
MN9D. MN9D dopaminergic cells were incubated for 1 hour 
with either citrate buffer (control), 1 ng/mL of DNSP-11 or 
GDNF prior to 100 f.LM 6-0HDA exposure for 15 min. Data 
are +SD, one-way ANOVA with Tukey's post hoc analysis, 
*p<0.05, **p<O.Ol, ***p<0.001 vs. control; #p<0.05, 
##p<0.01, ###p<O.OOl vs. 6-0HDA. As seen in FIGS. llC 
and D, 100 f.LM 6-0HDA significantly increased TIJNEL 
staining and caspase-3 activity in MN9D cells (FIGS. llC 
and D). Pretreatment with DNSP-11 or GDNF produced a 
significant reduction in the percent of TIJNEL positive cells 
and caspase-3 activity (FIGS. llC and D). Thus both DNSP-
11 and GDNF protect against 6-0HDA toxicity as demon-
strated by reductions in TUNEL staining at 24 h (FIG. llC) 
and caspase-3 (FIG. llD) activity at 3 h after 6-0HDA expo-
sure. 
Example 7 
Uptake of DNSP-11 into Neurons 
Additional studies were carried out to determine ifDNSP-
11 is actively taken up into dopamine-containing neurons in 
vivo. A single administration of30 flg ofDNSP-11 was deliv-
ered into the rat substantia nigra. Animals were euthanized at 
0.5, 1.5, 4, 24 and 48 hrs after injection to visualize distribu-
tion of DNSP-11 using antibodies raised against DNSP-11 
and the ubiquitinated form ofDNSP-11. DNSP-11 antibodies 
labelled the cytosol and neurites of neurons in the area of the 
substantia nigra within 30 minutes after injection. DNSP-11 
was taken up by neurons in both the substantia nigra, pars 
reticulata (SNr) and substantia nigra, pars compacta (SNc). 
The fluorescent immunostaining for DNSP-11, TH and the 
merger of photomicrographs from each showed that TH-
these cells, including an increase in the size ofTH+ neurons, 
which was not observed for DNSP-11 (Table 4). Photographs 
in FIG. llB of treated E14 primary dopaminergic neurons 
demonstrate that both GDNF and DNSP-11 treated cells (0.1 
ng/ml) displayed enhanced cell survival, neurite length, and 
total number of branches. 
In Table 1, cell survival and morphological parameters 
were quantified for control (citrate buffer) and experimental 
(0.1 ng/ml GDNF or 0.1 ng/ml DNSP-11) conditions. For 
morphology, five fields per well (minimum of 15 cells/field; 
3-4 independent experiments) were photographed at 20x 
magnification and quantified using a Bioquant Image Analy-
sis System. DNSP-11 increased cell survival and morpho-
logical parameters comparable to GDNF, including com-
bined neurite length and total branches. Soma size was not 
increased by the addition of DNSP-11. A one-way AN OVA 
was used to test for significance among groups, followed by a 
Newman-Keuls post hoc analysis. Significance between con-
trol and experimental conditions was determined at *p<0.05 
and **p<O.Ol. 
35 positive dopamine neurons populate the SNc and the ventral 
tegmental area (VTA). Higher power micrographs from the 
SNc. DNSP-11 immunostaining revealed uptake into the 
perikaryon, nucleus, and neurites ofTH+ cells. 
TABLE4 
GDNF DNSP-11 
Control 0.1 ng/ml Control 0.1 ng/ml 
Cell survival 100 ± 15 *158 ± 12 100 ± 16 *161 ± 17 
n~8 n~8 n~7 n~7 
Combined neurite 242 ± 12 **310 ± 16 222 ± 11 **306 ± 23 
length (urn) n ~ 135 n ~ 106 n~ 139 n ~59 
Soma size (um2 ) 171 ±4 177 ± 4 168 ± 3 165 ± 5 
n ~ 135 n ~ 106 n~ 139 n ~59 
Average branches 3.8 ± 0.2 **4.7 ± 0.2 3.1 ± 0.2 **4.4 ± 0.3 
per neuron n ~ 135 n ~ 106 n~ 139 n ~59 
To evaluate DNSP-11 's neuroprotective properties, 
DNSP-11 was compared to GDNF in its protection against 
At 1.5 hrs post-injection, staining forTH+ and DNSP-11 
40 showed overlap in the pars compacta of the substantia nigra 
and some labeling in the pars reticulata, supporting potential 
uptake of DNSP-11 into GABAergic neurons. Immunohis-
tochemical staining for DNSP-11 diminished 3 hrs after 
injection and was absent at 24 hrs and beyond, indicating that 
45 there is a rapid uptake of DNSP-11 into neurons. 
B65 dopaminergic cells were incubated with FITC-DNSP-
11 and Confocal microscopy images were used to follow the 
internalization ofDNSP-11-FITC-DNSP-11 (10 nM, green) 
into the cells. Immunofluorescence staining 3 hours after 
50 treatment showed that FITC-DNSP-11 was within the plasma 
membrane and is colocalized into the lysosomes. Mitochon-
drial staining showed that there is limited FITC-DNSP-11 
colocalization at 3 hours (data not shown). 
55 
60 
Example 8 
Effect ofDNSP-11 on Dopamine Neurochemistry 
Prior studies with GDNF have shown robust effects on both 
potassium and amphetamine-evoked release 28 days after a 
single injection into the rat substantia nigra (Hebert et a!. 
(1997) J. Pharm. Exp. Thera. 282: 760) indicating the func-
tional effects of this trophic factor on dopamine signaling in 
the normal rat striatum. In the present experiment, 30 flg of 
65 DNSP-11 was injected into the right substantia nigra of nor-
mal young male Fischer 344 rats. Twenty-eight days after 
injection, in vivo microdialysis was performed in these ani-
US 9,402,875 B2 
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Example 9 
Interaction of DNSP-11 with Protein Partners 
mals to investigate dopamine neurochemistry in the ipsilat-
eral striatum. Resting levels of dopamine, 3,4-dihydroxyphe-
nylacetic acid (DO PAC) and homovanillic acid (HVA) were 
significantly increased by over 100% in the DNSP-11 treated 
rats as compared to controls (FIG. 12A). These data indicate 5 
longer term effects of DNSP-11 on dopamine neuron func-
tion, and are analogous to prior results involving GDNF 
administration in rats and nonhuman primates. Winkler et a!. 
(1996) J. Neurosci. 16: 7206; Hebert eta!. (1996) J Pharma-
cal Exper Ther. 279: 1181-1190 (1996). 
The in vitro studies and in vivo measures of the effects of 
DNSP-11 led to an investigation of the potential neurorestor-
ative properties of DNSP-11 to damaged dopamine neurons 
in a unilateral rat model of PD. Fischer 344 rats received 
dual-site unilateral injections of 6-0HDA to produce exten-
sive destruction of the ascending dopaminergic system that 
resulted in a greater than 99% depletion of striatal dopamine 
content ipsilateral to the site of the 6-0HDA injections. Rats 
were tested 3-4 weeks after the injection of 6-0HDA using 
low-dose (0.05 mg/kg, i.p.) apomorphine-induced rotational 
behavior. In rats that rotated greater than 300 turns/60 min-
utes, 30 flg of DNSP-11 was injected into the ipsilateral 
substantia nigra. DNSP-11 produced a significant -50% 
decrease in apomorphine-induced rotational behavior that 
was significant 1 week after administration and this effect was 
maintained for at least 4 weeks after DNSP-11 (FIG. 12B). At 
In order to identify the interactions of DNSP-11 with pro-
tein partners and to gain insight into the cellular mechanisms 
involved with the actions ofDNSP-11, a pull-down assay was 
performed with homogenate from isolated substantia nigra of 
normal young Fischer 344 rats. Cytosolic and membrane 
10 fractions were collected and incubated with biotinylated 
DNSP-11 for 30 minutes. Bound proteins were pulled down 
by strepavidin magnetic beads, extensively washed to remove 
non-specific binders, eluted with solubilization/rehydration 
15 
buffer and separated by 2D-PAGE. 
Specifically, a solution of 25 f.LL GFRa1 (1 mg/mL) was 
incubated with 50 f.LL of Dynabeads® (Invitrogen) in wash 
and bind buffer (0.1 M sodium phosphate, pH 8.2, 0.01% 
Tween® 20) for 10 minutes at room temperature. The beads 
20 were then washed three times in 100 fll, of wash and bind 
buffer. 2 flg of GDNF was added and incubated for 1 hour at 
4° C. 25 f.LL GFRa1 (1 mg/mL) was incubated with 40 flg of 
biotinylated DNSP-11 (bDNSP-11) for 1 hour at 4 o C. They 
were then added to 50 f.LL of hydrophilic streptavidin mag-
25 netic beads (New England Biolabs) and incubated for an hour 
at 4° C. 
5 weeks, the substantia nigra and striatum from each rat was 
analyzed by high performance liquid chromatography 
coupled with electrochemical detection. A single injection of 
DNSP-11 was found to significantly increase levels of 30 
dopamine and the dopamine metabolite, DO PAC, by -100% 
in the substantia nigra, indicating that DNSP-11 has a pow-
erful neurotrophic-like restorative effect on dopamine neu-
rons in this animal model oflate stage PD (FIG. 12C). 
Several spots were observed in both the cytosolic and 
membrane fractions, indicating that DNSP-11 is able to bind 
proteins found within the substantia nigra. To identifY these 
binding partners, protein bands were excised from the gels, 
trypsin digested, and analyzed by MALDI-TOF mass spec-
trometry. From these preliminary studies, approximately 20 
proteins were identified. Of these, glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), a protein with a link to PD 
and apoptosis, was identified. This result was confirmed by in 
vitro pull down assays with pure GAPDH and DNSP-11. 
In addition, a pull-down assay of DNSP-11 with GFRa1 
indicated that the two molecules do not interact, like mature 
40 GDNF (FIG. 13; F-Flow through, E-Elution). Moreover, the 
absence of interaction between GFRa1 with DNSP-11 is 
supported by ELISA. 
As shown in FIG. 12A, 28 days after DNSP-11 or citrate 35 
buffer vehicle was delivered to the nigra! cell bodies, the 
DNSP-11 treatment group showed significantly higher basal 
neurochemical concentrations of DA, DOPAC and HVA. 
Basal DA increased from 26.0±2.7 nM in the vehicle treat-
ment group to 45.8±7.7 nM in the DNSP-11 treatment group 
(tc31 )=2.255 , p=0.0314). Basal concentrations of DOPAC 
increased from 3355±338 nM in the vehicle group to 
6544±836 nM in the DNSP-11 group (tc31 )=3.293, 
p=0.0025), and HVA, increased from 2419±251 nM with 
vehicle treatment to 4516±502 nM with DNSP-11 treatment 
(tc3o)=3.588, p=0.0012). All data were analyzed using a two-
tailed unpaired t-test * p<0.05. FIG. 12B shows the results of 
assessment of apomorphine (0.05 mg/kg) induced rotational 
behaviorpriorto infusion treatment (Pre) and once weekly for 
A gel filtration study was performed using a 120 mL 
Sephacryl S-200 column at a constant 1 mL/min flow rate. 
45 Individual300 f.LM solutions ofGAPDH (-150 kDa; FIG.14, 
dotted line) or GDNF (-30 kDa; FIG. 14, dashed line) eluted 
at expected retention times for their sizes of 50 min (FIG. 14, 
star) and 64 min (FIG.14, pound sign), respectively. When a 
pre-equilibrated (1 h), equimolar solution of GAPDH and 
50 GDNF was analyzed by gel filtration chromatography, two 
equally intense peaks were observed (FIG.14, solid line) with 
retention times identical to the individual solutions. These 
data demonstrate that GDNF does not interact with 
4 weeks after DNSP-11 or vehicle treatment. Drug-induced 
rotational behavior is expressed as a percentage of vehicle 
treatment and showed a significant decrease in rotational 
behavior beginning one week after DNSP-11 treatment that 
lasted for all 4 weeks post DNSP-11. The data were analyzed 
using a one-way ANOVA for repeated measures (Fc4 •39) 
=4.807, p=0.0005) with Bonferroni's multiple comparison 
test* p<0.05, ** p<0.01, *** p<O.OOl. FIG. 12C shows that 
DNSP-11 treatment significantly increased levels of DA, 
(74%) and DOPAC (132%) in the substantia nigra ofunilat-
eral6-0HDA-lesionedrats. DAcontentwas determined to be 60 
34.7±6.4 ng/g in the vehicle treatment group and 59.1±7.3 
ng/g in the DNSP-11 treatment group (tc13)=2.521, 
p=0.0265). DOPAC tissue content was determined to be 
GAPDH in solution, thereby providing evidence that 
55 DNSP-11 has an independent mechanism of action relative to 
mature GDNF. 
7.1 0±1.40 ng/g in the vehicle treatment group and 16.48±4.01 
ng/g (tc13)=2.33, p=0.0364) in the DNSP-11 treatment group. 65 
All data were analyzed using a two-tailed unpaired t-test, * 
p<0.05. 
Taken together, these data indicate that DNSP-11 exhibits 
potent neurotrophic actions analogous to GDNF, but likely 
signals through pathways that do not directly involve the 
GFRa1 receptor. 
The foregoing examples demonstrate that DNSP-11 shares 
many physiological and neurotrophic properties with mature 
GDNF, including neuroprotection and promoting differentia-
tion in primary dopamine neuron cell cultures; increasing 
dopamine release and metabolism in vivo; and decreasing 
apomorphine-induced rotations and enhancing dopamine 
function in the substantia nigra of 6-0HDA lesioned rats. 
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Example 10 
DNSP-11 Solubility and Stability 
The backbone secondary structure ofDNSP-11 was exam- 5 
ined using circular dichroism spectroscopy in the far-UV 
region (CD; University of Kentucky Center of Structural 
Biology). The DNSP-11 spectrum (FIG. 15A) displayed a 
broad minimum mean residue ellipticity (MRE) at 200 nm, 
indicative of a peptide that it is dynamic and samples multiple 10 
confirmations. Small shoulders between 208-230 nm indicate 
that DNSP-11 appears to be sampling polyproline II and other 
helical structures. Collectively, the spectrum of DNSP-11 
shows that it has characteristics of typical small, soluble, 
15 
functional peptides of similar length. 
Reverse Phase HPLC (RP-HPLC; FIG.15B); University of 
Kentucky Center of Structural Biology) and electrospray 
mass spectrometry (University of Kentucky Mass Spectrom-
etry Facility) were used to monitor at the stability ofDNSP- 20 
11. DNSP-11 was stored in citrate buffer (1 0 mM Citrate+ 150 
mM NaCI, pH 5.0) at -80° C. and 37° C. for 30 days. These 
temperatures were chosen based on their relevance to long 
term storage and use in future studies. The results of these 
studies showed that the peptides were stable at both tempera- 25 
tures for one month without any appreciable loss of peptide 
(FIG. 15C). 
Our analysis of the effects ofDNSP-11 on dopamine neu-
rons in the nigrostriatal system of the brain of young adult 
F344 rats at 28 days following a single injection of the pep- 30 
tide, demonstrated a surprising effect, i.e., an increase in basal 
tissue levels of the dopamine metabolite 3,4-dihydroxyphe-
nylacetic acid (DOPAC, see FIG. 16). The 100% increase in 
DOPAC was unprecedented in our numerous experiments 
over the past 20 years. In fact, we have never seen a dopam- 35 
ine-altering agent, which increases the metabolism of dopam-
ine by 1 00% and this effect was seen to persist for one month 
after a single injection ofDNSP-11 into the substantia nigra, 
which is the source of the dopamine-containing fibers mea-
sured in the striatum. GDNF, which augmented the evoked 40 
release of dopamine by over 100%, increased basal levels of 
DO PAC by only 20-25% in young and aged rats (Herbert eta!. 
30 
Our standard published procedures for immuncytochemi-
cal staining were used (e.g. Gash D Met a!., J Camp Neural. 
1995 December 18;363(3):345-58., Grondin eta!., 2002; Ai 
et a!., 2003). A polyclonal antibody was generated against 
DNSP-11 in rabbits (Alpha Diagnostic International, San 
Antonio, Tex.). Endogenous peroxidases were inactivated by 
incubation with 0.2% hydrogen peroxide (H20 2 ) for 10 min-
utes and background blocked with 4% normal serum, 1% 
bovine serum albumin (BSA) for 1 hour. Free floating sec-
tions were incubated in primary antisera. Sections were then 
exposed to the appropriate biotinylated IgG (Vecto Labs, 
Burlingame, Calif.) for 1 hour and then incubated in avidin-
biotin-peroxidase complex using Elite ABC Vectastain Kits 
(Vector Labs) for 1 hour. Some sections were double-labeled 
using procedures following our published procedures for 
immunocytochemical staining to identify cells with two 
markers (e.g. Ai eta!., 2003). 
Controls for immunostaining included the omission of pri-
mary antibodies and replacement of primary antibodies with 
normal serum of the same species. 
Results: A 30 flg bolus of DNSP-11 injected into the mid-
substantia nigra region using stereotaxic procedures spreads 
-3 mm in the anterior-posterior plane and up to -2 mm in the 
medial-lateral plane (FIG. 17) to cover most of the pars com-
pacta component of the nigra. DNSP-11 is taken up in the first 
30 minutes following injection by neurons and their axonal 
and dendritic processes. It is found in the cytoplasm and then 
perinuclear area and nucleus. At 24 hours after injection, 
some residual DNSP-11 can still be detected. There was no 
evidence of DNSP-11 by 48 hours post peptide administra-
tion. 
Stereotaxic injections of 30 flg DNSP-11 were also made 
into the striatum, hippocampus and cortex. Uptake was 
observed into neurons in both areas. Pyramidal neurons in the 
cortex accumulated DNSP-11. 
In summary, DNSP-11 is taken up within 30 minutes by 
neurons in all brain areas evaluated. The uptake sites appear to 
be specific for axons, dendrites, synaptic terminals and 
perikarya of nerve cells. DNSP-11 immunostaining is found 
in the cytoplasm and then in the nucleus. The half-life of 
DNSP-11 in the rat brain is under 24 hours. The areas of the 
brain studied (substantia nigra, striatum, hippocampus and 
cortex) have major roles in cognitive and motor functions. 
Tropic actions of DNSP-11 could protect these brain areas 
from injury and/or promote restoration from disease and 
injury processes. 
Example 12 
DNSP-11 Induced Changes in Genes Regulating 
Mitochondria/Functions 
J. Pharmacal. Exp. Therapeut. (1996) 279:1181-1190, and 
Hebert and Gerhardt, J. Pharmacal. Exp. Therapeut. (1997) 
282:760-768). Based on the results presented herein, and the 45 
knowledge that DOPAC is produced when dopamine is 
metabolized by monoamine oxidase B, (an enzyme on the 
outer membrane of mitochondria (Edmondson et a!, Curr. 
Med Chern (2004) 11(15:1983-93) and then the product of 
this reaction is metabolized by aldehyde dehydrogenase 50 
(which resides in the cytosol of cells) we reasoned that 
DNSP-11 increases mitochondrial functions and thereby 
increases monoamine oxidase levels. The following 
examples address this. 
Changes in expression of mitochondrial-associated genes 
in the substantia nigra (SN) of three young adult (5 month old) 
55 male F344 rats 48 hours following bilateral intranigral injec-
tions of DNSP-11 into the substantial nigra was assessed as 
follows. 
Example 11 
DNSP-11: Distribution, Uptake and Half-life in the 
Brain 
To assess the distribution, uptake and degradation of 
DNSP-11 in the brain, young adult male F344 rats, as a test 
organism, received injections of 30 flg DNSP-11 in the sub-
stantia nigra, hippocampus or cortex. They were euthanized 
by anesthesia overdose at various time points from 30 min-
utes to 48 hrs later and perfused through the heart with saline 
followed by paraformaldehyde. 
A 3 flg/fll DNSP-11 peptide solution was prepared in citrate 
buffer and filter sterilized. Stereotaxic injections were made 
60 of 30 flg DNSP-11 in 10 ul citrate buffer into the substantia 
nigra on each side of the brain. Controls received 10 flg 
injections of vehicle. Forty-eight hours later, the animals 
were euthanized, the brains quickly recovered and sectioned 
so that the bilateral SN could be dissected out as one block of 
65 tissue and snap frozen in liquid nitrogen. RNA was extracted 
from the SN samples for gene array analysis, which was 
conducted on Af:tymetrix Version II chips. A gene chip was 
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run for each of the six rats: three bilateral vehicle recipients, 
three bilateral 30 flg DNSP-11 recipients. 
Genes regulating mitochondrial functions were identified 
as the subset of genes on the microarray in the peptide-treated 
group having expression levels that were significantly 
increased or decreased as compared to the controls (Table 5). 
Biol Med. 2005 June 15;38(12):1543-52. Epub (2005 Mar. 
24)). Increased levels of Park 7 (DJ-1) are protective against 
Parkinson's disease (Thomas & Beal, Hum Mol Genet. 16 
Spec No. 2:R183-94 (2007 Oct. 15)) and increase levels of 
Presenilin 1 are believed to be protective against Alzheimer's 
disease (Das, Front Biosci. 13:822-32 9 (2008 Jan. 1)). In 
Fourteen genes were significantly up-regulated and five were both instances, it is a decreased or mutant form of the gene 
significantly down-regulated in DNSP-11 recipients. One that is closely linked to neurodegenerative diseases. The cyto-
10 
gene with increased expression was Monoamine Oxidase B, 
a finding consistent with the higher DO PAC levels mentioned 
earlier. A number of other genes with increased expression 
are associated with protection against oxidative damage: glu-
tathione/glutaredoxin, glutathione peroxidase and thiore- 15 
doxin (Koehler eta!., Antioxid Redox. Signal., 8(5-6):813-22 
(2006); Comhair & ErzurumAntioxid Redox Signal., 7(1-2): 
72-9. (2005) ). Catalase is an important enzyme converting the 
chrome c oxidase subunits are components of the terminal 
respiratory complex producing energy via oxidative phos-
phorylation. 
The caspases having increased expression are associated 
with apotosis (Kataoka, Crit Rev lmmunol. 25(1):31-58 
(2005); Vassar, Neuron 54(5):671-3 (2007)). Without wishing 
to be bound by theory, the increased expression oflow levels 
strongoxidanthydrogenperoxidetowater-andoxygen(Cal- 20 capases may reflect a nonspecific inflammatory reaction to 
deron IL eta!., PLoS ONE. 1 :e70 (2006 Dec. 20)). Peroxyre- the mild physical injury induced by the needle track and 
doxin is another antioxidant (Rhee, Chae & Kim, Free Radic injection of material into the substantia nigra. 
TABLES 
Changes in expression level post DNSP-11 delivery 
SYMBOL DESCRIPTION PEPTIDE CONTROL P-VALUE FOLD CHANGE 
GLRX2 
CASP8 
glutaredoxin 2 
caspase 8, apoptosis-related cysteine 
peptidase 
TXN2 thioredoxin 2 
MAOB monoamine oxidase B 
COX6A2 cytochrome c oxidase subunit Via 
polypeptide2 
GPX7 
CAT 
PRDX5 
PSEN1 
CASP3 
COX17 
glutathione peroxidase 7 
catalase 
peroxiredoxin 5 
presenilin 1 (Alzheimer disease 3) 
caspase 3, apoptosis-related cysteine 
peptidase 
COX17 cytochrome c oxidase assembly 
homolog (S. cerevisiae) 
PARK7 DJ-1 protective against Parkinson's disease 
COX6B1 cytochrome c oxidase subunit Vib 
polypeptide 1 (ubiquitous) 
NDUFA7 NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 7, 14.5 kDa 
APP amyloid beta (A4) precursor protein 
(peptidase nexin-11, Alzheimer disease) 
MAPK9 mitogen-activated protein kinase 9 
MAPK10 mitogen-activated protein kinase 10 
BACEI beta-site APP-cleaving enzyme 1 
MAP2K4 mitogen-activated protein kinase kinase 4 
3618.7 
219.4 
1511.9 
2199.8 
814.1 
194.2 
2828.2 
5569.8 
673.5 
421.4 
2326.1 
5299.2 
7869.7 
3125.4 
9734.4 
770.7 
505.0 
451.6 
2422.4 
3472.2 
178.1 
1378.5 
1974.2 
520.6 
183.8 
271a.O 
4790.1 
563.2 
367.5 
2017.8 
5159.4 
7536.6 
2943.0 
10117.2 
930.0 
552.8 
510.6 
2744.4 
<0.001 
0.006 
0.010 
0.012 
0.014 
O.G15 
O.G15 
0.020 
0.022 
0.024 
0.025 
0.032 
0.044 
0.046 
0.006 
0.007 
0.008 
0.016 
0.043 
1.09 
1.25 
1.10 
1.13 
1.75 
1.19 
1.09 
1.13 
1.16 
1.18 
1.11 
1.02 
1.04 
1.07 
-1.08 
-1.21 
-1.08 
-1.09 
-1.12 
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The foregoing results indicate that DNSP-11 treatment 
significantly effects the expression of genes regulating mito-
chondrial functions. The changes in gene expression would 
be neuroprotective against free radical oxidative damage to 
mitochondria. This would decrease mitochondrial wear and 
tear from oxidative respiratory processes producing energy, 
increasing the functional lifespan of mitochondria in a neu-
rons and synapses. 
Example 13 
DNSP-11 Increases State III Mitochondria/ 
Respiration in the Rat Nigro striatal System 
As our previous studies had demonstrated that injections of 
30 flg DNSP-11 into the substantia nigra had marked effects 
28 days post administration with elevated levels of dopamine 
and dopamine metabolites in the nigrostriatal system (sub-
stantia nigra and its projections to the striatum), we quantified 
the effects of DNSP-11 on mitochondria respiration and 
enzyme activity in the nigrostriatal system of young adult 
F344 rats at 28 days post injection. 
Six five-month-old male F344 rats received bilateral 
intranigral injections of 30 flg DNSP-11. Six age and sex-
matched controls received injections of the same volume of 
vehicle (citrate buffer). Twenty-eight days after test material 
administration, the animals were euthanized by C02 anesthe-
sia and the brain samples rapidly dissected. The striatum and 
substantia nigra were isolated quickly and carefully using a 
rat brain matrix for F344 rats. 
Mitochondrial respiration was assessed using a miniature 
Clark-type electrode, in a sealed, thermostatic and continu-
ously stirred chamber. Mitochondria were added to the cham-
ber to yield a final protein concentration of 1 mg/ml. The 
substrate concentrations were 5.0 mM/2.5 mM for glutamate/ 
malate and pyruvate/malate or 10 mM for succinate+2.5 IM 
rotenone or a-glycerophosphate. State 3 respiration was ini-
tiated by the addition of 150 11mols ADP. The respiratory 
control ratio was calculated as respiration in the presence of 
ADP (state 3)/respiration in absence ofADP (state 4).ADP/O 
ratios were determined by dividing the amount of ADP phos-
phorylated during State III respiration by the amount of oxy-
gen consumed. NAD-linked substrates, e.g. glutamate and 
pyruvate, utilize complexes I, III, IV in their oxidation, suc-
cinate utilizes complexes II, III, IV and a-glycerophosphate 
ultilizes III, IV. Thus impaired oxidation ofNAD-linked sub-
strates, but normal oxidation of succinate or a-glycerophos-
phate implies a defect at the level of complex I. Impaired 
oxidation of both NAD-linked and succinate oxidation 
implies a defect in both complex I and II and/or in complex III 
and IV which can be elucidated by the use of a-glycerophos-
phate. 
The chamber was also equipped with fluorescence/absor-
bance probes which allow us to also measure simultaneously 
ROS production in real-time with all other parameters. ROS 
production was measured using the H20 2 indicator dichlo-
rodihydrofluorescein diacetate (H2 DCFDA, Molecular 
Probes). Ten f.LM H2 DCFDA, which is made fresh before each 
use, was added to the chamber and the relative amount of 
mitochondria) H20 2 and free radical production measured as 
34 
f.LM H2 DCFDA or Amplex Red, a H2 0 2 indicator that is 
extramitochondrial. Controls include the addition of the elec-
tron transport chain inhibitor antimycin (complex III inhibi-
tor, yields maximum ROS production independent of ll W), 
oligomycin (inhibits ATPase yielding maximum llW-depen-
dent ROS production) and the uncoupler FCCP (inhibits all 
NP-dependent ROS production). 
The mitochondria were freeze-thawed and sonicated three 
times for measuring all the complexes activities. Complex I 
10 (NADH dehydrogenase) assay is performed in 2.5 mM KP04 
buffer (pH 7.2) containing mitochondrial protein (6 flg), 5 
mM MgC12 , 1 mM KCN, 1 mg/ml BSA, and 150 f.LM NADH 
at 30° C., the reaction initiated by addition of coenzyme Q-1 
15 
(50 f.LM). In this reaction ubiquinone 1 was the final electron 
accepter. The decrease in NADH absorbance at 340 11m was 
monitored. The assay was also performed in the presence of 
rotenone (10 f.LM) to determine the rotenone-insensitive and 
the rotenone-sensitive complex I enzyme activity. Complex II 
20 (succinate dehydrogenase) activity was measured by the rate 
of reduction of 2,6-Dichloroindophenol. The reaction mix-
ture contained 100 mM KP04 buffer, 20 mM succinate, 10 
f.LM EDTA, 0.01% Triton, 1 flg/1 OOfll coenzyme Q2 contain-
ing mitochondria) protein (6 flg) at 30° C. and the reaction 
25 was initiated by the addition of0.07% 2,6-Dichloroindophe-
nol. Decreased in absorbance was monitored at 600 lJm. 
Complex IV (cytochrome c oxidase) activity was measured in 
10 mM KP04 buffer and 50 f.LM reduced cytochrome c. The 
reaction was initiated by addition of 6 flg mitochondria) pro-
30 tein. Rate of oxidation of cytochrome c was measured by 
measuring the decrease in absorbance of reduced cytochrome 
c, observed at 550 nm. 
As shown in FIG. 18, there was a trend towards an increase 
in State III oxidative phosphorylation at 28 days post treat-
35 ment in the substantia nigra. However, with an n=2, the dif-
ference was not significant with a two-tailed t-test. The effects 
reached statistical significance in the striatum, which is 
heavily innervated by dopamine fibers from the substantia 
nigra forming synapses on striatial medium spiny neurons. 
40 Evidence described in Example 12 indicates that DNSP-11 
was taken up within 30 minutes into neuritic processes and 
cell bodies of neurons. Soon thereafter, immunoreactive 
DNSP-11 was found in the nucleus. The effects at 28 days on 
dopamine and metabolite levels and on mitochondria demon-
45 strate that DNSP-11 treatment initiates genetic changes that 
last for long periods, at least one month, and without wishing 
to be bound by theory, this may occur perhaps through recep-
tors involving transcribing factors. 
Within 30 minutes following a 30 ug injection ofDNSP-11 
so into the F344 rat substantia nigra, the broad distribution of the 
compound through the substantia nigra (SN) region of the 
midbrain was evident (FIG. 17, panels A, B). At higher mag-
nification (FIG. 17 panels C, D) uptake of the peptide by 
neurons (arrows) could be discerned. At very high magnifi-
55 cation (FIG. 17 panel E), punctate-immunoreactive staining 
ofDNSP-11 was present in neuritic processes, cytoplasm and 
the perinuclear area of the cell body (arrows). The pattern of 
immunoreactivity was similar at 90 minutes post injection 
(FIG. 17 panel B), with prominent labeling in DNSP-11 in 
60 cells and neuritic processes (FIG. 17, panel D). Immunostain-
ing was more sensitive using fluorescent techniques (FIG.17, 
panel F), highlighting DNSP-11 immunoreactivity in the 
cytoplasm and nuclei of neurons. The cells in F were double-
labeled for the neuronal marker NeuN and DNSP-11. 
an increase in fluorescence. Again the same rationale as above 
can be used to pinpoint the source ofROS production. Addi-
tionally, ROS production was monitored over time in a Syn-
ergy HT plate reader or a Shimadzu RF -5301 spectrofluo-
rimetre with stirred and water-jacketed cuvett holders 65 
(excitation 490 l]m, emissions 526 flill; ex550 l]m, em590 
l]llill, respectively) at 37° C. for 15 min in the presence of 10 
By improving mitochondrial functions in neurons and their 
synapses, DNSP-11 treatment could significantly restore 
neural networks affected in neurodegenerative diseases, 
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including Alzheimer's disease and Parkinson's disease, 
improving cognitive functions in the former and improved 
motor functions in the latter. 
Example 14 
The Neurorestorative Properties ofDNSP-11 to 
Damaged Dopamine Neurons in a Unilateral Rat 
Model of PD. 
Fischer 344 rats received dual-site unilateral injections of 
6-0HDA to produce extensive destruction of the ascending 
dopaminergic system that resulted in a greater than 99% 
depletion of striatal dopamine content ipsilateral to the site of 
the 6-0HDA injections. Rats were tested 3-4 weeks after the 
injection of 6-0HDA using low-dose (0.05 mg/kg, i.p.) apo-
morphine to induce rotational behavior. In rats that rotated 
greater than 300 turns/ 60 minutes, 30 flg of DNSP-11 was 
injected into the ipsilateral substantia nigra. DNSP-11 pro-
duced a significant -50% decrease in apomorphine-induced 
rotational behavior that was significant 1 week after admin-
istration and this effect was maintained for at least 4 weeks 
after DNSP-11 (FIG. 19A). At 5 weeks, the substantia nigra 
and striatum from each rat was analyzed by high performance 
liquid chromatography coupled with electrochemical detec-
tion. A single injection of DNSP-11 was found to signifi-
cantly increase levels of dopamine and the dopamine metabo-
lite, DOPAC, by -100% in the substantia nigra, supporting 
that DNSP-11 has a powerful neurotrophic-like/mitochon-
drogenic restorative effect on dopamine neurons in this ani-
mal model oflate stage PD (FIG. 19B). 
Example 15 
Protection of MN9D and B65 Cells from 
Mitochondrial Toxins 
MN9D cells and B65 cells were cultured in Dulbecco's 
Modified Eagle's Medium (DMEM; 11995 (containing pyri-
doxol HCl); Sigma, St. Louis, Mo.) supplemented with 10% 
fetal bovine serum (HyC!one, Logan, Utah), 50 U/mL peni-
cillin and streptomycin. For each assay the cells were treated 
with mitochondrial-specific environmental toxins, i.e., 
MPP+, rotenone, and/or TaClo, and with or without DNSP-
11. After incubation with the toxins, the cells were plated on 
24-well poly-D-lysine plates (50,000 cells/well) for TUNEL 
assay (as described below) or 100,000 cell/well for caspase-3 
assay in D MEM medium with 1% ( v /v) penicillin -streptomy-
cin only (as described below). 
A. JC-1 Mitochondrial Membrane Potential Assay 
36 
mean±S.E.M. for mean optical measurements. The values are 
expressed as percent of the mean control values ±S.E.M. and 
analyzed usingANOVA. 
FIG. 20 A-D depicts the mitochondrial potential ofMN9D 
5 cells (A) and B65 cells (B-D)) incubated in the presence 
IviPP+, rotenone, or TaClo with or without DNSP-11 and 
demonstrated that the DNSP-11 protects the cells from the 
deleterious effects ofMPP+, rotenone and TaClo exposure. 
B. Cellular Apoptosis: TUNEL Staining 
10 
Terminal deoxynucleotidyl transferase mediated X-dUTP 
nicked end DNA labeling of cells (TUNEL staining) was used 
to assess cells undergoing apoptosis. After treatment with 
either 50 nM, 1 OOnM or 250nM MPP+, or 50 nM, 100 nM or 
250nMrotenone, or 10 f.LM, 25f1Mor 50 f.LMTaClo, for 1 to 12 
hours at 37° C. in 5% C02 , following pretreatment with or 
15 without 10 nM or 100 nM DNSP-11 for 1 to 30 minutes, 
MN9D cells were fixed and labeled to assess degenerative 
nuclear changes as indicated by the extent of high-molecular 
weight DNA strand breaks. The biotinylated nucleotides are 
detected by using streptavidin-horseradish peroxidase conju-
20 gate followed by the substrate, diaminobenzidine (DAB). The 
enzyme reaction generates an insoluble colored precipitate 
where DNA fragmentation has occurred. DAB-stained 
samples were examined using a light microscope. Cell were 
counted with 20x magnification ( 4 random fields/well), 4 
25 wells per group. Ratio between apoptotic cells and total cells 
was calculated. This experiment was repeated 3 times and 
performed using anApoptosis detection TACS TdTKit (R&D 
System). 
FIG. 20 E-G depicts the results of the TUNEL staining 
30 assay ofMN9D cells incubated with MPP, rotenone or TaClo 
with or without DNSP-11 and demonstrates that DNSP-11 
provides MN9D cells with protection from the deleterious 
effects of MPP+, rotenone and TaClo exposure. 
35 
C. Caspase-3 Activity Assay 
B65 cells were plated on 24-well poly-D-lysine plates in 
DMEM and 50u/ml penicillin and streptomycin. Cells incu-
bated in either 50 nM, 100 nM, or 250 nM rotenone or 10 f.LM, 
25 1flM or 50 f.LM TaClo for 1 to 12 hours at 37° C. in 5% C02 , 
following pretreatment (1 to 30 minutes) with or without 10 
40 nM or 100 nM DNSP-11. The cells were then lysed and 
protein level measured by BCA assay (BioRad). The protein 
level were normalized for every experiment. The Enz Chek 
Caspase-3 Kit (Invitrogen) was used to detect caspase-3 
activity and fluorescence was read on fluorescence reader 
45 (excitation/emission 496/520 nm). Data are expressed as% of 
control and were repeated a minimnm of three times. 
FIG. 20 H-I depicts the capase-3 activity of B65 cells 
treated with rotenone or TaClo, with or without DNSP-11. 
FIG. 20 H-I demonstrates that DNSP-11 provides B65 cells 
50 with protection from the deleterious effects of TaClo and 
MN9D and B65 cells were treated with either 50 nM, 100 
nM, 250 nM, 500 nM, 2.5 f.LM or 5 f.LM rotenone, 50 nM, 100 
nM, 250 nM 1-methyl-4-phenylpyridinium (MPP+ ), or 10 
f.LM, 25 f.LM, 50 f.LM, 100 f.LM, 150 f.LM or 2001-trichlorom-
ethyl-1,2,3,4-tetrahydro-~-carboline (TaClo), for 1 to 12 55 
hours and then incubated at 37° C. in 5% C02 following 
pretreatment (1 to 30 minutes) with or without 100 nM or 10 
nM DNSP-11. After treatment with rotenone, MPP+ or TaClo 
and incubation with DNSP-11, the cells were incubated for 30 
minutes at 3 7° C. in a 5% C02 incubator in the presence of 10 60 
f.LM of the green fluorescent JC-1 (5,5', 6,6'-tetrachloro-1,1', 
3,3'-tetraethylbenzimidazolyl-cabo-cyanine iodine, T-3168 
(Invitrogen)) and then washed in Locke's solution. Optical 
measurements were acquired with excitation at 485 nm and 
emission at 527 nm, and 590 nm. The levels of fluorescence at 65 
each emission wavelengths were quantified and ratio of mea-
surements was assessed. The pertinent data are given as 
rotenone exposure. 
FIG. 20 A-I demonstrates that treatment with DNSP-11 
provided significant protection to MN9D neuronal cells and 
B65 cells against MPP+, rotenone and/or TaClo toxicity, as 
demonstrated by the reduction in TUNEL staining, reduced 
Capase 3 activity and the increased level of mitochondrial 
potential detected in cells incubated in the presence ofDNSP-
11. DNSP-11 alone had no significant effect on MN9D or B65 
as determined in the mitochodrial potential assay, TUNEL 
staining assay or caspase-3 activity assay. 
Example 16 
ERK1/2 Activation by GDNF and DNSP-11 
It has been suggested that Erk activation affects mitochon-
drial function. The results presented herein demonstration 
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that cells treated with GDNF and DNSP-11 have elevated 
levels of activated Erk as determined by western blot analysis. 
MN9D and B65 cell were cultured in DMEM; 11995 (con-
taining pyridoxal HCl; Sigma, St. Louis, Mo.) supplemented 
with 10% fetal bovine serum (HyC!one, Logan, Utah), 50 
U/mL penicillin and streptomycin with DNSP-11 (0.1 uM or 
1 uM) or GDNF (50 ng/ml) for 20 minutes. The cells were 
then solubilized in Triton-X-100/glycerol lysis buffer and 
subjected to electrophoresis and western blotting as partially 
described previously (Jiang eta!., Mol Biol Cell 14:859-70 10 
(2003) ). To detect phosphorylated Erk ( #43 77 Cell Signaling) 
and ERK (#4696 Cell Signaling) by immunoblotting, the 
cells were directly lysed in the sample loading buffer. Sec-
ondary IRDye 700X and IRDye800 conjugated, fluorescent 
antibodies (Rockland Inc.) were used to detect signal with 15 
Odyssey v3 .0 scam1ing software. Several blots were analyzed 
to determine the linear range of the fluorescence signals, and 
quantifications were performed using densitometry analysis. 
Our results demonstrate that like GDNF, DNSP-11 increases 
significantly the phosphorylation ofErk1/2 (the ratio of phos- 20 
phorylated to non-phosphorylated Erkl/2) in MN9D and B65 
cells (FIG. 21). 
Example 17 
25 
Oxygen Consumption Rate 
38 
nM, 2.5 nM and 5 nM rotenone (FIG. 23 B). Dosages were 
optimized for analysis by the Seahorse XF24 flux analyzer. 
An increase in reserve respiration capacity allow the mito-
chondria to effectively respond to the mitochondrial-specific 
toxins disclosed above. An increase in mitochondria reserve 
respiration capacity is consistent with the in vitro protection 
from cytotoxins by DNSP-11 and with the in vivo increases in 
dopamine release and metabolism observed for Fischer 344 
rats after a single DNSP-11 injection into the substantia nigra 
that are disclosed herein. 
These results further demonstrate that ADNS peptides of 
this invention provide mitochondrial protection and restora-
tion from various stresses, including enviroumental toxin 
exposure, particularly toxins that inhibit mitochondrial Com-
plex I activity. In both MN9D and B65 dopaminergic neurons, 
DNSP-11 provides significant protection against TaClo, 
MPP+, and rotenone as evidenced by the of mitochondrial 
potentials, caspase-3 activity, and TUNEL staining results 
presented herein. DNSP-11 also protects cellular oxygen 
consumption rates from TaClo and rotenone exposure and 
increases mitochondrial reserve respiration capacity in 
MN9D neurons. 
The evidence reported herein demonstrates that treatment 
with the ADNS peptides of this invention, e.g., DNSP-11, 
improve mitochondrial function and further that treatments 
with the ADNS peptides of this invention, e.g., DNSP-11, 
promote behavioral restoration in diseases such as Alzhe-
Complex I inhibitors have been demonstrated to increase 
mitochondrial dysfunction, which leads to the formation of 
reactive oxygen species (ROS), decrease in the formation of 
ATP, and ultimately cell death. The ability of cells to respond 
to stress under conditions of increased energy demand is, in 
large part, influenced by the bioenergetic capacity of mito-
chondria. The reserve respiration capacity is a measure of the 
cell's ability to manage and overcome stress-such as that 
encountered during exposure to toxins, injury, aging, and 
genetic abnormalities (Choi eta!., Journal of Neurochemistry 
109: 1179-1191.2009). 
30 imer's disease and Parkinson's disease, and aging processes 
associated with dopinergic deficiencies. The evidence 
reported herein also demonstrates that treatment with the 
DNSP-11 peptide of this invention, prevents, or lessens, the 
35 effects of mitochondrial toxins, particularly mitochondrial 
Real-time measurement of oxygen consumption rate 
(OCR) of intact DNSP-11-treated MN9D cells, in the pres- 40 
ence and absence of Complex I toxins, rotenone 1-5 11M or 
TaClo 100-150 f.LM, were performed utilizing the Seahorse 
XF -24 extracellular flux analyzer. This instrument allows the 
simultaneous measurement of the mitochondrial bioenerget-
ics from 20 independent cell culture samples, without the 45 
mitochondrial isolation (and thus higher quantities of sample) 
needed for the standard (lower throughput) Clark-type elec-
trode chamber. Details regarding the methods used for the 
Seahorse analysis were recently described in detail (Saner-
beck et a!., Journal of Neuroscience Methods 198:36-43 50 
(2011) incorporated herein by reference). 
Briefly, following sensor preparation, calibration, and dose 
optimization, the basal and maximal oxygen consumption 
rates (OCR) were measured in intact MN9D neuronal cells in 
the absence and presence of 1 f.LM DNSP-11. As shown, in 55 
FIG. 22 DNSP-11 had no significant effect on the basal OCR 
compared to control treatment. Following electron transport 
chain uncoupling by 100 nM FCCP to measure the maximal 
OCR, treatment ofMN9D neurons with DNSP-11 had nearly 
a 60% increase (p<0.001) versus control. The ratio between 60 
the maximal and basal OCR is a measure of the reserve 
complex I toxins, on mitochodrial and mitochondria-contain-
ing cells. 
The foregoing examples demonstrate that DNSP-11: is 
taken up by neurons in the cortex, hippocampus and substan-
tia nigra, areas important in cognitive and motor functions; 
significantly increases the expression of genes associated 
with mitochondrial functions in the brain, including genes for 
proteins that protect mitochondria from oxidative damage 
leading to functional deterioration, and; increases energy pro-
duction in brain mitochondria for extended periods. DNSP-
11 was shown to protect mitochodria from the deleterious 
effects of toxins such as MPP+, rotenone and TaClo which 
target the mitochondrial complex I enzyme activity. 
Increased energy production in mitochondria in synapses 
is posited to promote restoration of neural circuitry leading to 
restoration of cognitive and motor functions. 
While the present invention has been described with refer-
ence to specific embodiments, this application is intended to 
cover those various changes and substitutions that may be 
made by those of ordinary skill in the art without departing 
from the spirit and scope of the appended claims. 
The publications discussed herein are provided solely for 
their disclosure prior to the filing date of the present applica-
tion. Nothing herein is to be construed as an admission that 
the present invention is not entitled to antedate such publica-
tion by virtue of prior invention. Further, the dates of publi-
cation provided may be different from the actual publication 
respiratory capacity of neurons, thus treatment of DNSP-11 
significantly increases the reserve respiratory capacity of 
MN9D cells, primarily due to its effects on the maximal 
respiratory capacity. 
DNSP-11 also showed protection of the basal and maximal 
OCRs from 100 f.LM and 150 f.LM TaClo (FIGS. 23 A) and 1 
65 dates, which may need to be independently confirmed. All 
publications cited herein are hereby incorporated by refer-
ence in their entirety. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 15 
<210> SEQ ID NO 1 
<211> LENGTH, 134 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 1 
Ser Pro Asp Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg 
1 5 10 15 
Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg 
20 25 30 
Gly Gln Arg Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu 
35 40 45 
Asn Val Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile 
50 55 60 
Phe Arg Tyr Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp 
65 70 75 80 
Lys Ile Leu Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys 
85 90 95 
Val Gly Gln Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser 
100 105 110 
Phe Leu Asp Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala 
115 120 125 
Lys Arg Cys Gly Cys Ile 
130 
<210> SEQ ID NO 2 
<211> LENGTH, 17 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 2 
Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly 
1 5 10 15 
Lys 
<210> SEQ ID NO 3 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 3 
Phe Pro Leu Pro Ala 
1 5 
<210> SEQ ID NO 4 
<211> LENGTH, 11 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 4 
Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu 
40 
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-continued 
1 
<210> SEQ ID NO 5 
<211> LENGTH, 402 
<212> TYPE, DNA 
5 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) .. (402) 
<400> SEQUENCE, 5 
10 
tea cca gat aaa caa atg gca gtg ctt cct aga aga gag egg aat egg 48 
Ser Pro Asp Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg 
1 5 10 15 
cag get gca get gee aac cca gag aat tee aga gga aaa ggt egg aga 96 
Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg 
20 25 30 
ggc cag agg ggc aaa aac egg ggt tgt gtc tta act gca ata cat tta 144 
Gly Gln Arg Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu 
35 40 45 
aat gtc act gac ttg ggt ctg ggc tat gaa ace aag gag gaa ctg att 192 
Asn Val Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile 
50 55 60 
ttt agg tac tgc age ggc tct tgc gat gca get gag aca acg tac gac 240 
Phe Arg Tyr Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp 
65 70 75 80 
aaa ata ttg aaa aac tta tee aga aat aga agg ctg gtg agt gac aaa 288 
Lys Ile Leu Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys 
85 90 95 
gta ggg cag gca tgt tgc aga ccc ate gee ttt gat gat gac ctg tcg 336 
Val Gly Gln Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser 
100 105 110 
ttt tta gat gat aac ctg gtt tac cat att eta aga aag cat tee get 384 
Phe Leu Asp Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala 
115 120 125 
aaa agg tgt gga tgt ate 402 
Lys Arg Cys Gly Cys Ile 
130 
<210> SEQ ID NO 6 
<211> LENGTH, 211 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
Met Lys Leu Trp Asp Val Val Ala Val Cys Leu Val Leu Leu His Thr 
1 5 10 15 
Ala Ser Ala Phe Pro Leu Pro Ala Gly Lys Arg Pro Pro Glu Ala Pro 
20 25 30 
Ala Glu Asp Arg Ser Leu Gly Arg Arg Arg Ala Pro Phe Ala Leu Ser 
35 40 45 
Ser Asp Ser Asn Met Pro Glu Asp Tyr Pro Asp Gln Phe Asp Asp Val 
50 55 60 
Met Asp Phe Ile Gln Ala Thr Ile Lys Arg Leu Lys Arg Ser Pro Asp 
65 70 75 80 
Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg Gln Ala Ala 
85 90 95 
Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg Gly Gln Arg 
100 105 110 
Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu Asn Val Thr 
42 
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-continued 
115 120 125 
Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr 
130 135 140 
Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu 
145 150 155 160 
Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln 
165 170 175 
Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp 
180 185 190 
Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala Lys Arg Cys 
195 200 205 
Gly Cys Ile 
210 
<210> SEQ ID NO 7 
<211> LENGTH, 192 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
Phe Pro Leu Pro Ala Gly Lys Arg Pro Pro Glu Ala Pro Ala Glu Asp 
1 5 10 15 
Arg Ser Leu Gly Arg Arg Arg Ala Pro Phe Ala Leu Ser Ser Asp Ser 
20 25 30 
Asn Met Pro Glu Asp Tyr Pro Asp Gln Phe Asp Asp Val Met Asp Phe 
35 40 45 
Ile Gln Ala Thr Ile Lys Arg Leu Lys Arg Ser Pro Asp Lys Gln Met 
50 55 60 
Ala Val Leu Pro Arg Arg Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn 
65 70 75 80 
Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg Gly Gln Arg Gly Lys Asn 
85 90 95 
Arg Gly Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly 
100 105 110 
Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly 
115 120 125 
Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu Lys Asn Leu 
130 135 140 
Ser Arg Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln Ala Cys Cys 
145 150 155 160 
Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu 
165 170 175 
Val Tyr His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys Ile 
180 185 190 
<210> SEQ ID NO 8 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 8 
Phe Pro Leu Pro Ala Gly Lys Arg 
1 5 
44 
<210> SEQ ID NO 9 
<211> LENGTH, 14 
<212> TYPE, PRT 
45 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 9 
Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu Gly Arg Arg 
1 
<210> SEQ ID NO 10 
<211> LENGTH, 20 
<212> TYPE, PRT 
5 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
10 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 10 
Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly 
1 5 10 15 
Lys Gly Arg Arg 
20 
<210> SEQ ID NO 11 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 11 
Phe Pro Leu Pro Ala Gly 
1 5 
<210> SEQ ID NO 12 
<211> LENGTH, 12 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 12 
Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu Gly 
1 5 10 
<210> SEQ ID NO 13 
<211> LENGTH, 18 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 13 
Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly 
1 5 10 15 
Lys Gly 
<210> SEQ ID NO 14 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
46 
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-continued 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 14 
Lys Arg Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu Gly Arg Arg 
1 5 10 15 
<210> SEQ ID NO 15 
<211> LENGTH, 22 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 15 
Arg Arg Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser 
1 5 10 15 
Arg Gly Lys Gly Arg Arg 
20 
What is claimed is: 
1. A method for treating a condition associated with a 
deficiency in mitochondrial complex I enzyme activity in a 
subject comprising administering to a subject in need thereof 
a pharmaceutically effective amount of a composition com-
prising 
(a) a purified Amidated Dopamine Neuron Stimulating 
peptide (ADNS peptide) comprising the amino acid 
sequence ERNRQAAAANPENSRGK-amide (SEQ ID 
NO: 2); 
(b) a purified ADNS peptide comprising the amino acid 
sequence FPLPA-amide (SEQ ID NO: 3); or 
(c) a purified ADNS peptide comprising the amino acid 
sequence PPEAPAEDRSL-amide (SEQ ID NO: 4), or 
mixtures thereof, 
and at least one of a pharmaceutically acceptable vehicle, 
excipient, and diluent, 
25 
30 
35 
wherein the composition is administered nasally, 
wherein the subject in need thereof has a traumatic brain 
injury, and 
wherein the composition is administered in an amount that 
restores mitochondrial activity as evidenced by an 
increase in levels of at least one of dopamine and a 
dopamine metabolite in the subject. 
2. The method of claim 1, wherein the ADNS peptide is a 
purified ADNS peptide comprising the amino acid sequence 
ERNRQAAAANPENSRGK-amide (SEQ ID NO: 2). 
3. The method of claim 1, wherein theADNS peptide is a 
purified ADNS peptide comprising the amino acid sequence 
FPLPA-amide (SEQ ID NO: 3). 
4. The method of claim 1, wherein the ADNS peptide is a 
purified ADNS peptide comprising the amino acid sequence 
40 PPEAPAEDRSL-amide (SEQ ID NO: 4). 
* * * * * 
